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ABSTRACT
REGULATION OF CCR5 USE ON CD4+ LYMPHOCYTES BY R5X4 HIV-1
Lamorris M. Loftin
Ronald G. Collman
HIV-1 strains that use CCR5 predominate after transmission and during the
asymptomatic period of disease. However, in up to half of infected people, variants that
use CXCR4 emerge, coincident with accelerated disease progression. The earliest
CXCR4 using strains to appear, called R5X4 viruses, usually retain CCR5 use. Prototype
R5X4 HIV-1 isolates infect macrophages using CCR5 and CXCR4, but CD4+
lymphocyte infection by these viruses is mediated predominantly by CXCR4. Here, we
sought to identify obstacles to CCR5 use on CD4+ lymphocytes by R5X4 HIV-1. Using
a panel of R5X4 Envs we found that, although CXCR4 was the predominant coreceptor
used to infect CD4+ lymphocytes, there was a spectrum of CCR5 use. Greater CCR5 use
on lymphocytes correlated with relative resistance to inhibition by CCR5 mAbs and small
molecule antagonists in CCR5+ indicator cells. Increasing CCR5 expression on primary
lymphocytes through cytokine stimulation or lentiviral transduction increased the
proportion of entry mediated by CCR5 for all R5X4 isolates except 89.6. Env
dependence on CCR5 density was then evaluated using a cell line in which levels of CD4
and CCR5 could be independently regulated. At non-limiting CD4 levels, strains with
greater lymphocyte CCR5 use were better able to exploit limiting levels of CCR5,
whereas those that used lymphocyte CCR5 poorly were more sensitive to reductions in
CCR5 levels. Evaluation of the V3 sequences of the R5X4 viruses using algorithms that
iii

predict viral phenotype indicated an association between greater CCR5 use on
lymphocytes and a predicted non-syncytium inducing phenotype. Introduction of an
R306S mutation in the Env V3 domain of 89.6 enhanced its ability to use CCR5 at low
levels and switched its preference to CCR5 for lymphocyte entry. Residue R306 in the
89.6 and C2-16 Envs was also associated with greater dependence on the amino terminus
of CCR5 for infection. Thus, lymphocyte CCR5 is used by some R5X4 strains to a
variable degree, low CCR5 expression coupled with inefficient Env-CCR5 interactions
are the principal obstacles to lymphocyte CCR5 use by R5X4 HIV-1, and the spectrum of
lymphocyte CCR5 use by R5X4 isolates is determined by variation in Env-CCR5
interactions.
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Chapter I - Introduction

1

Origin of the HIV-1 pandemic
Human Immunodeficiency Virus – type 1 (HIV-1), the causative agent of
acquired immunodeficiency syndrome (AIDS), is a lentivirus in the family Retroviridae.
HIV-1 can be grouped into three separate phylogenetic lineages that each entered the
human population through cross species transmission of Simian Immunodeficiency Virus
(SIV) from either chimpanzees (Group M and Group N) (Keele et al., 2006) or gorillas
(Group O) (Van Heuverswyn et al., 2006) in west Africa. Recently a fourth lineage
(Group P) (Plantier et al., 2009) was proposed, suggesting that cross-species transmission
of SIV may still occur. HIV-1 from groups N and O are found almost exclusively in
West Africa (Ayouba et al., 2000; Peeters et al., 1997); however, HIV-1 from group M
spread beyond Africa leading to the global pandemic (Buonaguro, Tornesello, and
Buonaguro, 2007). Since the early 20th century, the likely period during which HIV-1
Group M entered the human population (95), the evolution of this group from a common
ancestor has resulted in the formation of distinct genetic subgroups, clades A-K, as well
as numerous circulating recombinant forms of the virus (Buonaguro, Tornesello, and
Buonaguro, 2007). The greatest diversity of HIV-1 Group M is found in Sub-Saharan
Africa, while the pandemic in other parts of the globe is characterized by a high
prevalence of one or a few specific clades or recombinant forms of the virus (Hemelaar et
al., 2006). Over 25 million people have died of infection by HIV-1, and currently 33
million people globally, including 22 million in Sub-Saharan Africa, are infected by HIV1 making it imperative that we understand the pathogenic mechanisms of this virus
(Merson, 2006; UNAIDS-Epidemic-Update, 2009).
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Overview of HIV-1 pathogenesis
HIV-1 is an insidious virus that, in the absence of antiretroviral therapy, slowly
erodes the capacity of the immune system to respond to pathogens, which ultimately
causes individuals to succumb to AIDS in an average of 5-7 years (Costagliola et al.,
1989; Ward et al., 1989). The virus is spread by exposure to blood and other bodily
fluids containing HIV-1, which occurs through blood product transfusion, IV drug use,
perinatal exposure and, most commonly, during sexual contact (Curran et al., 1984;
Harris et al., 1983; Scott et al., 1984).
HIV-1 infection and pathogenesis are studied using relevant human lymphoid
cells and tissues ex vivo or SIV infection in non-human primates, and disease progression
is monitored by specific measures that are adversely affected by the virus (Fig. 1.1).
Following mucosal infection by SIV (Stahl-Hennig et al., 1999; Zhang et al., 1999) or
HIV-1 infection of vaginal explant tissue (Collins et al., 2000; Gupta et al., 2002), virus is
first found in small foci of infected resting and activated memory CD4+ lymphocytes and
then later in macrophages and dendritic cells at the initial sites of infection. Within two
weeks of SIV infection, virus disseminates from the site of local infection and
amplification to local draining lymph nodes (Miller et al., 2005; Stahl-Hennig et al.,
1999). From there, the virus travels through the lymphatic and vascular systems to other
lymphoid tissue including the gut associated lymphoid tissue (GALT) (Miller et al., 2005;
Stahl-Hennig et al., 1999). The majority of activated, memory CD4+ lymphocytes in the
body are found in the GALT, and HIV-1 infection of CD4+ lymphocytes in this
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CD4+ lymphocyte (% of total)
Figure 1.1. Markers of disease progression during HIV-1 infection.
Acute infection by HIV-1 is characterized by a rapid decline in CD4+ lymphocytes in multiple
compartments that is coincident with a rapid increase in viral load. During this stage, the immune system is
activated to respond to the virus. CD4+ lymphocytes in peripheral blood, but not in gut mucosal tissue,
rebound as viral load decreases marking the transition to the chronic phase of infection. During the chronic
phase, CD4+ lymphocytes in peripheral blood continue to decline and immune activation increases, which
is thought to contribute to the immune exhaustion seen later in disease. Near the onset of AIDS, there is a
loss of viral control that leads to a spike in viral load, depletion of the peripheral blood CD4+ lymphocytes
and death. R5X4 strains typically appear near the onset of AIDS. Image obtained from Grossman, Z. et al.
Nature Medicine 2006.
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compartment leads to rapid and massive cell loss that is sustained throughout disease (Fig
1.1) (Brenchley et al., 2004; Schieferdecker et al., 1992; Schneider et al., 1994). HIV-1
replication in the GALT invokes a robust immune response and induces apoptosis of
intestinal epithelium that damages the lining of the gut (Li et al., 2008; Sankaran et al.,
2008; Schmitz et al., 2001). Microbial products are thought to enter peripheral blood as a
consequence of the breakdown of the intestinal barrier and induce immune activation that
increases as disease progresses and has been hypothesized to directly contribute to the
immunodeficiency that occurs at the end of disease (Fig 1.1) (Brenchley et al., 2006).
Although HIV-1 infection after the acute phase is clinically asymptomatic, covert
viral replication proceeds for years until the final stage of disease (Embretson et al., 1993;
Pantaleo et al., 1993). Humoral and cellular HIV-1-specific immune responses arise
weeks after transmission; however, in most cases, they fail to adequately control viral
replication, instead providing selective pressure that contributes to viral evolution (Allen
et al., 2005; Wei et al., 2003). As HIV-1 disease progresses, the number of CD4+
lymphocytes in blood slowly declines (Polk et al., 1987). The opportunistic infections
that characterize AIDS typically begin to occur once CD4+ lymphocyte levels fall below
a threshold (Eyster et al., 1989), and infected individuals ultimately die from an inability
to clear virulent as well as opportunistic microorganisms (Fig. 1.1) (Quagliarello, 1982).
HIV-1 pathogenesis begins at the interface between the virus and cellular
membranes. HIV-1 requires a receptor, CD4 (Dalgleish et al., 1984; Klatzmann et al.,
1984), and a seven-transmembrane domain chemokine coreceptor, either CCR5 (Choe et
al., 1996; Deng et al., 1996) or CXCR4 (Berson et al., 1996; Feng et al., 1996), for
infection of target cells. Viruses are typically classified based on the coreceptors they use
5

to infect CD4+ cells lines: R5 viruses use CCR5, X4 viruses use CXCR4, while R5X4
viruses are able to use either coreceptor (Robertson et al., 2000). Differences in
coreceptor use between HIV-1 variants have important implications for transmission and
pathogenesis. R5 HIV-1 predominates in the early and asymptomatic stages of infection
(Schuitemaker et al., 1991); however, in up to 50% of subtype B-infected individuals,
viruses that use CXCR4 emerge (Spijkerman et al., 1995). Memory lymphocytes are the
preferential targets of R5 viruses, but the emergence of CXCR4 use leads to an expansion
in target cell tropism to include naïve lymphocytes as well (Blaak et al., 2000; Ostrowski
et al., 1999). The appearance of these variants and the expanded tropism that results is
associated with an accelerated decline in the number of CD4+ lymphocytes in peripheral
blood and rapid progression to AIDS and death (Koot et al., 1993), but presently, it is
unclear whether the emergence of CXCR4-using viruses is a cause or consequence of
immune decline. Interestingly, regardless of virus quasispecies in the donor or the route
of transmission, nearly all HIV-1 infections are initiated by R5 viruses (van't Wout et al.,
1994; Zhu et al., 1993). Although there is evidence suggesting mutational barriers and
selective immune pressure oppose the emergence of CXCR4-using viruses (Harouse et
al., 2003; Pastore, Ramos, and Mosier, 2004), it is unclear what factors regulate the
appearance of these variants and why predominately R5 strains transmit. R5X4 viruses
are the first CXCR4-using variants to appear (van Rij et al., 2000), and despite CCR5 use
on indicator cells, these viruses rarely establish infections after transmission (Cornelissen
et al., 1995; Pasquier et al., 1998). Consequently, studies focused on R5X4 HIV-1 may
shed light on these two critical aspects of HIV-1 infection: the emergence of CXCR4 use
and the bottleneck at transmission that selects for R5 viruses.
6

Figure 1.2. Steps in the gp120 mediated membrane fusion process.
The HIV-1 Env and the cellular receptor (CD4) and coreceptors (CCR5/CXCR4) are shown on the viral
and host cell membranes, respectively. CD4 binding leads to conformational changes in gp120 that result
in the formation of a coreceptor-binding site. Coreceptor binding causes additional structural changes in
gp120 that lead to insertion of the fusion peptide of gp41 into the target cell membrane. Creation of the
six-helix bundle in gp41 brings the virus and target cell membrane into close proximity ultimately resulting
in membrane fusion and viral entry. This image was modified from Nathanson and Overbaugh, Viral
Pathogenesis and Immunity 2006
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Function and structure of the HIV-1 envelope protein
The HIV-1 lipid membrane is studded with the envelope (Env) glycoprotein,
which is arranged on the surface of the virion as a trimer (Gelderblom et al., 1987). This
protein is composed of gp120, the surface subunit, non-covalently attached to the
transmembrane subunit gp41, which contains the fusion peptide (Earl, Doms, and Moss,
1990; Freed, Myers, and Risser, 1990). As outlined in Figure 1.2, HIV-1 entry is a
multistep process that begins with binding between gp120 and CD4 (Dalgleish et al.,
1984; Klatzmann et al., 1984). In addition to tethering the virus to target cells, CD4gp120 binding also triggers conformational changes in Env that create a coreceptor
binding site (Sattentau and Moore, 1991). A number of seven-transmembrane G-proteincoupled receptors serve as coreceptors for HIV-1 in vitro (Edinger et al., 1998a; Edinger
et al., 1998b), but only CCR5 and CXCR4 are thought to play a significant role for
infection in vivo (Scarlatti et al., 1997). Coreceptor binding is required to complete the
conformational changes in Env that lead to membrane fusion (Mkrtchyan et al., 2005;
Oravecz, Pall, and Norcross, 1996).
Virus-host membrane fusion is mediated by gp41. Gp41 has a an N-terminal
fusion peptide that is inserted into the target cell membrane following receptor binding
(Freed, Myers, and Risser, 1990; Gallaher, 1987) and two heptad repeats (HR1 and 2)
that fold back on each other following insertion of the fusion peptide (Chan et al., 1997;
Weissenhorn et al., 1997). Formation of this 6-helix bundle brings the HIV-1 and target
cell membranes into close proximity (Melikyan et al., 2000). The exact mechanisms that
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Figure 1.3. Env structure and variability.
The 2D amino acid structure of the R3A Env is pictured with the location of the variable loops denoted
(A). Predicted N-linked glycosylation sites are indicated by black dots, and the N-terminal leader sequence
is cleaved where indicated. The structure of gp120 is shown without the variable loops (B) or CD4triggered with the V3 loop (C). (A) The molecular surface of monomeric gp120 core showing the inner
domain (left side) and the heavily glycosylated outer domain (right side), which is modeled with complex
(light blue) or high-mannose (dark blue) sugars. The location of the variable loops is indicated. Color
coding signifies the sequence variability of the indicated residues: red, highly conserved between primate
lentiviruses, orange, highly conserved between HIV-1 viruses, yellow, variable between HIV-1 viruses,
green, significant variability between HIV-1 viruses. (B) CD4-triggered gp120 structure with V3 loop
extended toward the cell surface. The CD4 structure is superimposed showing the orientation of the gp120
trimer towards the host cell membrane. R3A 2D sequence obtained from G. Leslie (U. of Pa.). Gp120
images from Wyatt, R. et al. Nature 1998 (B), and Huang, C. et al. Science 2005 (C)
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join the viral and cellular lipid bilayers are unknown, but following membrane fusion, the
capsid core is released into the cell. Upon viral entry, reverse transcription, nuclear
import, integration of viral cDNA, viral gene expression, mRNA export, protein synthesis
and virion assembly occur, ultimately leading to the formation of new HIV-1 viruses
(Greene and Peterlin, 2002).
The conformational changes that have to occur in gp120 for entry to proceed are
directly related to the complex structure of the protein. The surface subunit of Env can
be divided based on patterns of genetic diversity between isolates into five conserved
regions and five variable regions, V1-V5, which correspond to disulfide bonded loops
(Fig. 1.3a) (Starcich et al., 1986). Additionally, gp120 is heavily glycosylated (Leonard
et al., 1990). Structural studies of gp120 monomer without its variable loops reveal a
core that is divided into an inner and outer domain (Fig. 1.3b) (Chen et al., 2005; Kwong
et al., 1998). The more conserved inner domain forms the interacting surface within the
trimer, while the glycosylated outer domain is exposed (Kwong et al., 1998). The CD4
binding site and portions of the coreceptor binding region, including the bridging sheet,
are non-contiguous on the surface of gp120, and the coreceptor binding domains are also
partially concealed by variable loops V1/V2 and V3 (Chen et al., 2005). CD4 binding
causes conformational changes, primarily within the inner domain, that result in
formation of the bridging sheet and extension of the V3 loop toward the cell surface,
ultimately facilitating coreceptor binding (Fig. 1.3c) (Huang et al., 2005; Kwong et al.,
1998).
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Molecular determinants of coreceptor use
The V3 loop is the most critical determinant of coreceptor use by HIV-1. The V3
loop is typically around 35 amino acids long and its structure consists of a base, stem and
tip (Leonard et al., 1990). The tip and stem of V3 are thought to interact with the extra
cellular loops of the coreceptor, while the base interacts with the coreceptor N-terminus
(Huang et al., 2007; Huang et al., 2005). Studies have shown that only a few mutations
within V3 are necessary to alter coreceptor use (de Jong et al., 1992a; Shioda, Levy, and
Cheng-Mayer, 1992). The presence of positively charged amino acids at positions 11 and
24 or 25 within the stem of V3 are associated with the ability to use CXCR4 (Cardozo et
al., 2007; de Jong et al., 1992a; Fouchier et al., 1992). Moreover, deletion of three amino
acids in the stem of V3, ∆9-12, eliminates CXCR4 use by prototype R5X4 viruses, while
deletions within the base of V3 abolish CCR5 use by these strains (Nolan, Jordan, and
Hoxie, 2008). Another characteristic frequently associated with CXCR4 use by HIV-1 is
a high net positive charge within V3 (Fouchier et al., 1992). Post-translational
modifications within V3 can also impact viral coreceptor use; the presence of N-linked
glycosylation in the base of V3 has been shown to determine CCR5 versus CXCR4 use
for some isolates (Ogert et al., 2001; Pollakis et al., 2001).
The bridging sheet and V1/V2 loops are in close proximity to the coreceptorbinding site, and changes within these regions can also have implications for coreceptor
use. Mutations within the bridging sheet can increase sensitivity to CCR5 or CXCR4
antagonists, indicating that this domain contributes to the efficiency of interaction with
coreceptor (Reeves et al., 2002). Mutations within V1/V2 also affect how efficiently Env
interacts with the coreceptor. Removing either of two N-linked glycans within the V1/V2
11

domain of DH12, an R5X4 virus, decreased CCR5 and CXCR4-mediated infection
(Ogert et al., 2001). Furthermore, replacing the V1/V2 of R5 Envs with the
corresponding domains from Envs that use CXCR4 can permit use of this coreceptor
(Cho et al., 1998; Pollakis et al., 2001), and the efficiency of CXCR4 use in this context
is regulated, in part, by glycosylation within V1/V2 (Pollakis et al., 2001). As critical
determinants of coreceptor use, the bridging sheet, V1/V2 and V3 also influence target
cell tropism.

Target cell tropism and viral phenotype
HIV-1 entry is a critical aspect of viral pathogenesis and a primary determinant of
which cell types are infected by the virus. CD4, CCR5 and CXCR4 are expressed on a
number of immune cells including T helper lymphocytes, monocytes, macrophages and
dendritic cells (Bleul et al., 1997; Terhorst et al., 1980; Wood, Warner, and Warnke,
1983; Zaitseva et al., 1997). CD4+ lymphocytes are the primary targets for HIV-1
infection and replication in vivo (Massari et al., 1990; Spear et al., 1990), while
macrophages are though to be a source of viral replication in numerous tissues (Eilbott et
al., 1989; Jeffrey et al., 1991). Although HIV-1 infects monocytes and dendritic cells in
vivo, infection of these cells is infrequent (Cameron et al., 1992; Spear et al., 1990), and
in the case of monocytes, is more common late in disease (McElrath, Pruett, and Cohn,
1989). Maturation-dependent intracellular blocks to HIV-1 replication in dendritic cells
and monocytes may explain why a low percentage of these cells are infected in vivo
(Bakri et al., 2001; Sonza et al., 1996).
12

L-R5

B-R5

R5X4

P-X4

LA-X4

Virus

Figure 1.4. HIV-1 coreceptor use and target cell tropism.
Target cell tropism is indicated for the particular HIV-1 virus. L-R5, lymph node derived R5 isolates that
poorly infect primary macrophages, B-R5, brain derived R5 viruses infect macrophages and lymphocytes;
P-X4, primary isolate X4 viruses infect all three cell types; LA-X4, lab-adapted X4 viruses infect primary
lymphocytes, and R5X4 viruses infect both primary cell types. Illustration modified from Collman and
Goodenow. Journal of Immunology 2006
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Early characterization of HIV-1 target cell tropism revealed that some viral
isolates infected primary CD4+ lymphocytes and lymphocyte cell lines but not
macrophages. These isolates were called syncytium-inducing (SI) or T cell (T) tropic
isolates because of their ability to induce cell-cell fusion, or syncytia, in CD4+
lymphocyte cell lines (Fig. 1.4). SI isolates grew rapidly in vitro and were typically
recovered at late stages of infection (Asjo et al., 1986; Tersmette et al., 1988). Another
class of HIV-1 isolates was found at earlier stages of disease. These isolates infected
CD4+ macrophages and primary lymphocytes, replicated slowly, did not infect CD4+
transformed cell lines (and thus did not induce syncytia in them) and were therefore
called non-syncytium-inducing (NSI) or macrophage (M) tropic isolates (Fig. 1.4) (Asjo
et al., 1986; Tersmette et al., 1988). Interestingly, M-tropic isolates did not infect T cell
lines and most T-tropic isolates replicated poorly in macrophages (Schuitemaker et al.,
1991; Schwartz et al., 1989). Following the identification of CCR5 and CXCR4 as
coreceptors, it became apparent that differences in target cell tropism for M-tropic and Ttropic isolates were in large part related to target cell expression of CCR5 or CXCR4,
respectively, and current classification schemes are now largely based on coreceptor use.
R5 viruses use CCR5 for infection and X4 use CXCR4, while R5X4 viruses can infect
cells expressing CCR5 or CXCR4 (Berger et al., 1998).

Coreceptor use and viral tropism
The combination of receptor and coreceptors expressed on a cell clearly
influences HIV-1 tropism. However, viruses within a strain can vary considerably in the
14

use of CCR5 or CXCR4 when expressed on different cells, which also has an impact on
cell tropism and pathogenesis. As mentioned, lab-adapted and primary X4 isolates
efficiently infect primary lymphocytes using CXCR4 (Gartner et al., 1986; Tersmette et
al., 1988); however, lab-adapted X4 isolates show a reduced ability to use CXCR4 on
macrophages when compared to some X4 primary isolates (Fig. 1.4) (Verani et al., 1998;
Yi et al., 1999). This difference in tropism results from the inability of lab-adapted X4
viruses to use the low levels of CXCR4 expressed on primary macrophages (Tokunaga et
al., 2001), which may be a consequence of prolonged passage on CD4+ cell lines in vitro.
There are other examples of physiologically relevant variation in receptor use within a
strain. R5 Envs cloned from brain typically infect macrophages more effectively than R5
Envs recovered from peripheral blood and tissue despite similar infection levels on
lymphocytes (Fig. 1.4) (Peters et al., 2004; Peters et al., 2006). Furthermore, differences
in macrophage tropism between brain-derived R5 viruses have important implications for
viral pathogenesis. Neurovirulent R5 HIV-1 from patients with dementia show an even
greater capacity to infect macrophages than R5 viruses isolated from brains of patients
with no signs of neurological impairment (Gorry et al., 2002a). In both cases, enhanced
macrophage tropism is mediated either by increased CCR5 affinity (Gorry et al., 2002a)
or by an ability to efficiently utilize low levels of CD4 or CCR5 for infection (Dunfee et
al., 2006; Gorry et al., 2002a; Peters et al., 2004).
The relationship between coreceptor use and target cell tropism is quite complex
and is unique for each HIV-1 strain. It is critical that we fully understand the variation in
coreceptor use by HIV-1 strains and its affects on target cell tropism because of the
important role these two factors play in HIV-1 transmission and pathogenesis.
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Emergence of CXCR4 use: an overview
Longitudinal studies of HIV-1 reveal that R5 isolates predominate during the
early and the asymptomatic period of disease (Schuitemaker et al., 1991). However,
nearly half of subtype-B infected individuals develop CXCR4-using variants (Spijkerman
et al., 1995) (as do a number of people infected with other subtypes, except for subtype C
which acquires CXCR4 use infrequently (Abebe et al., 1999; Tscherning et al., 1998)) .
The emergence of CXCR4-using viruses is associated with accelerated loss of CD4+
lymphocytes and rapid progression to AIDS (Koot et al., 1993). However, it remains
unclear whether viruses capable of using CXCR4 arise in response to a weakened
immune system, whether these viruses cause the accelerated immune decline associated
with their emergence or if both phenomena occur. Unraveling this complex relationship
as well as identifying the factors that regulate the emergence of CXCR4 use will help
more clearly define the role of viral evolution in disease progression and may have
implications for other stages of infection.

Emergence of CXCR4 use: intrinsic mutational barriers
In some cases, as little as two amino acid changes are sufficient to convert a virus
from R5 to R5X4 (Kiselyeva et al., 2007; Pastore, Ramos, and Mosier, 2004), yet
variants that use CXCR4 arise in only half of infected patients, suggesting barriers to
their emergence. Studies of viral evolution in vitro and in vivo reveal complex
mutational pathways from CCR5 to CXCR4 use that are beset with obstacles. In one
study, nearly all R5X4 viruses derived in vitro replicated more poorly and were more
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sensitive to CCR5 antagonists than the parental R5 viruses (Pastore, Ramos, and Mosier,
2004). Additionally, when the mutations that accrued were individually reinserted into
the parental R5 virus, the mutations within the V3 loop that switched coreceptor use
resulted in non-functional viruses. Mutations within the V3 loop only resulted in
functional Envs with CXCR4 use when they were preceded by mutations in V1/V2
(Pastore et al., 2006). In a patient followed for years before and after coreceptor switch,
there was a reduction in the efficiency of CCR5 use by R5 viruses and rapid divergence,
not only within V3, but in the V4/V5 loops as well, prior to the emergence of R5X4
viruses (Coetzer et al., 2008). These studies suggest that mutations within other domains
of Env are required prior to or concurrent with the changes in V3 for CXCR4 use to
emerge, and this multistep process is a barrier to the acquisition of CXCR4 because it
negatively impacts CCR5-mediated entry and frequently results in non-functional Envs.

Emergence of CXCR4 use: immune suppression of CXCR4-using viruses
The difficult mutational pathways that lead to CXCR4 use are an intrinsic
obstacle to coreceptor switching. However, the immune response to the virus also
appears to impede this process. It has been reported that, following the acquisition of
CXCR4 use, X4 viruses are more sensitive to neutralizing antibodies than coexisting R5
viruses (Bunnik et al., 2007). Support for the notion that CXCR4-using viruses are
preferentially targeted by the host immune response also comes from acute infection. A
few anecdotal cases have suggested that after a brief period of replication, CXCR4-using
HIV-1 variants can be selectively suppressed following coinfection with viruses that use
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CCR5 (Cornelissen et al., 1995; Veenstra et al., 1995). A similar observation was made
in a macaque coinfection study in which the R5 SHIV remained detectable while the X4
SHIV became undetectable in some animals coincident with the establishment of a
SHIV-specific immune response. Depletion of CD8+ lymphocytes in these animals led
to the reemergence of the X4 SHIV to levels similar to those of the R5 SHIV, and the X4
SHIV returned to undetectable levels after the CD8+ lymphocytes rebounded (Harouse et
al., 2003). These findings suggest the immune response to HIV-1 suppresses X4 variants
and that the loss of immune control may contribute to the emergence of CXCR4-using
viruses. On the other hand, recent data suggests that most people who sexually acquire
HIV become infected with a single variant, which is usually R5 (although whether X4
viruses are suppressed by local innate immune responses during mucosal replication is
unknown) (Keele et al., 2008a).
While it remains unresolved, there is a substantial body of work suggesting that
immune decline precedes the emergence of CXCR4 use because the antiviral immune
response is more effective against these strains. The transmission and establishment of
R5X4 viruses have been associated with poor humoral and cytotoxic cellular immune
responses (Dalmau et al., 2009), although, it is not clear whether pronounced immune
dysfunction enabled R5X4 infection or whether infection by R5X4 strains precipitated
the immune destruction. In this regard, macaque models of coreceptor switch may be
informative. The emergence of CXCR4-using SHIVs in macaques infected with CCR5using viruses occurred in animals with high viral load, poor cellular immune response
and undetectable antibody response to the virus (Ho et al., 2007; Ren et al., 2010),
suggesting that immune decline precedes the appearance of variants that use CXCR4.
18

Emergence of CXCR4 use: CCR5+ target cell depletion
Another factor proposed to drive the acquisition of CXCR4 use is target cell
depletion. R5 HIV-1 preferentially infects memory lymphocytes, while naïve
lymphocytes, which lack CCR5 expression, are rarely targeted by these viruses (Blaak et
al., 2000; Rabin et al., 1999). Acquisition of CXCR4 use results in a marked increase in
infection of naïve lymphocytes (Blaak et al., 2000; Ostrowski et al., 1999). Preferential
infection of CCR5+ memory lymphocytes coupled with expanded targeting of naïve
lymphocytes following acquisition of CXCR4 use has lead to the hypothesis that
depletion of CCR5+ targets cells creates pressure that selects for viruses with CXCR4
use. CCR5+ target cell depletion and lack of immune control are not mutually exclusive;
these factors may act in concert to promote the acquisition of CXCR4 use. One
interpretation of the results from the macaque model of coreceptor switch mentioned
above is that poor immune control results in high levels of viral replication, increasing
the chances of the emergence of mutant viruses that use CXCR4 while creating an
environment that would allow greater depletion of CCR5+ target cells.
Conversely, an expansion in target cell tropism coupled with more rapid,
cytopathic infection by R5X4 and X4 viruses suggests a viral component to the decline in
cell numbers seen when these viruses are present. Infection by viruses that use CCR5 or
CXCR4 are equally cytopathic for their target cells in vitro (Kwa et al., 2001) and in ex
vivo lymphoid tissue (Grivel and Margolis, 1999). However, in blood, central and
effector memory as well as naïve CD4+ lymphocytes express CXCR4, resulting in much
greater lymphocyte depletion following infection with X4 and R5X4 viruses (Grivel and
Margolis, 1999; Kwa et al., 2001). On the other hand, in some CD4+ lymphocytes
19

subsets, such as resting memory cells, CXCR4-using viruses are more cytopathic (Zhou
et al., 2008), and these variants induce substantially more apoptosis in uninfected
bystander cells in lymphoid tissue compared to R5 viruses (Jekle et al., 2003). Animal
models also indicate that infection with X4 SHIV is more pathogenic than R5 SHIV
infection (Harouse et al., 1999; Nishimura et al., 2004), resulting in rapid depletion of
peripheral CD4+ lymphocytes, including naïve cells (Nishimura et al., 2005). Greater
infection of naïve lymphocytes likely impairs lymphocyte differentiation and exacerbates
immune decline. Although rare, in the instances in which CXCR4-using HIV-1 is
transmitted and establishes infection, CD4+ lymphocyte numbers decline rapidly and
progression to AIDS is much faster than the time frame following R5 infection (Yu et al.,
1998).

HIV-1 coreceptor use and transmission
Heterosexual intercourse is the most common route of HIV-1 transmission, but it
is nonetheless a very inefficient process. The probability of HIV-1 transmission from an
infected individual is infrequent, ranging from 0.04-0.38% per sex act (Boily et al.,
2009). However, HIV-1 transmission through other routes occurs at higher rates; the
mother-to-child transmission rate, pre- and intrapartum combined, is approximately 20%
(Kourtis et al., 2006). Efforts to understand HIV-1 transmission in different settings have
revealed a bottleneck at transmission that is associated with genotypic and phenotypic
selection of newly transmitted HIV-1 variants.
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Figure 1.5. Selective transmission of R5 HIV-1 from donor to recipient.
Regardless of the composition of the viral quasispecies in the donor, only R5 viruses are transmitted to the recipient. It is unclear
what factors impede the transmission of CXCR4 using viruses, or what selectively promotes the transmission of R5 strains. R5 target
cell tropism and X4 immune suppression are two possible barriers to transmission of X4 strains, but there are likely others. It is clear
that certain features are common in viruses from the recipient, such as the requirement for CCR5 use, which suggests selection
targeted at the viral Env.
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HIV-1 transmission is associated with a loss in genetic diversity from the donor to
the recipient that suggests a selective barrier to transmission. HIV-1 infection is
generally associated with high levels of genetic diversity (Hahn et al., 1986; Saag et al.,
1988). However, after transmission, viral diversity in the recipient is much lower than in
the donor, and this reduced diversity is most evident in the env gene (Verhofstede et al.,
2003; Wolinsky et al., 1992; Zhu et al., 1993). In fact, in the majority of new sexually
transmitted HIV-1 infections the env is completely homogeneous (Abrahams et al., 2009;
Keele et al., 2008a). Furthermore, recent studies using PCR amplification and
phylogenetic reconstruction of the successfully transmitted virus indicate a single viral
variant is usually responsible for seeding infection in the recipient (~80%) with two or
more variants responsible for the rest (Abrahams et al., 2009; Keele et al., 2008a).
A number of classic studies suggested that genetic homogenization in the
recipient was associated with selection at mucosal transmission that favored Mtropic/NSI isolates with specific exclusion of T-tropic/SI variants. In these studies,
viruses from the acute phase of infection were highly M-tropic where as T-tropic variants
did not arise until later stages of disease (Schuitemaker et al., 1992; van't Wout et al.,
1994; Zhu et al., 1993). The preponderance of M-tropic variants in a recipient during the
earliest periods following transmission was seen even when the donor harbored T-tropic
variants (van't Wout et al., 1994; Zhu et al., 1993), and a few anecdotal studies indicated
that SI variants could be selectively suppressed following transmission (Cornelissen et
al., 1995; Pratt et al., 1995). These early studies concluded that the ability to replicate in
macrophages is essential for establishing infection in recipients and implied that
macrophages are likely a major source of virus replication during acute infection.
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However, more recent in vitro and in vivo studies strongly suggest CD4+ lymphocytes
are the first cells infected after mucosal transmission (Gupta et al., 2002; Zhang et al.,
1999), variants from periods shortly after transmission do not have enhanced macrophage
tropism (Isaacman-Beck et al., 2009), and the single, founder virus responsible for
establishing infection after transmission actually replicates significantly better in CD4+
lymphocytes than macrophages (Salazar-Gonzalez et al., 2009).
It remains unclear whether target cell tropism is a factor in the bottleneck between
donor and recipient, but it is apparent that selection for R5 variants and exclusion of
CXCR4-using viruses occurs during HIV-1 transmission in association with
characteristic changes in Env. The V3 domain in Env is a major determinant of target
cell tropism, and initial characterization of V3 within Envs from acute infection
suggested selection at transmission that leads to a homogeneous population (Hwang et
al., 1991; McNearney et al., 1992; Zhang et al., 1993). The discovery of CCR5 as the
receptor for M-tropic viruses and the finding that V3 is the principal determinant of
coreceptor use provided a genotypic basis for the phenotypic selection observed at
transmission (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Doranz et al.,
1996). Furthermore, the identification of individuals that are protected from HIV-1
infection due to a 32 base pair deletion in the CCR5 gene, which prevents its expression
on the cell surface, confirms CCR5 use is required for transmission (Liu et al., 1996;
Samson et al., 1996). The requirement for CCR5 at transmission also suggests that V3,
the major determinant of coreceptor use, is either a direct or an indirect target of selection
during transmission. Additionally selection at transmission may also affect other regions
of Env. Envs recovered from the earliest time point after transmission of subtype A or C
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HIV-1 have shorter V1/V2 or V1-V4 length, respectively, and reduced N-linked
glycosylation (Chohan et al., 2005; Derdeyn et al., 2004) when compared to matched
donors. For subtype C, these changes are associated with greater sensitivity to
neutralization by donor antibody (Derdeyn et al., 2004). However, these differences in
Env appear to be subtype-dependent, since there are no changes in either Env length or
the number of N-linked glycosylation sites following transmission of subtype B viruses
(Chohan et al., 2005).
Selection for CCR5 use clearly occurs during transmission and is required for
HIV-1 to establish infection in a recipient. Preferential immune suppression of CXCR4using viruses may be one mechanism that accounts for this selection, although it remains
unclear whether this is the principal means of exclusion or whether CXCR4-using strains
are not transmitted for other reasons such as the inability to use CCR5 on a particular cell
type.

Transmission, CCR5 use and tropism by R5X4 HIV-1
It is unclear why particular viral strains are the target of selection during
transmission, which makes the study of R5X4 viruses intriguing and potentially
informative. These viruses can infect indicator cells expressing either coreceptor, yet a
dependence on CCR5 or CXCR4 for infection is associated with drastically different
outcomes following HIV-1 transmission. R5 strains predominate following viral
transmission whereas R5X4 viruses are typically not found during the early or
asymptomatic period of infection (van't Wout et al., 1994). If variants that use CXCR4
24

are selected against, R5X4 viruses may be subject to the same repressive forces that are
thought to oppose transmission of X4 viruses. Alternatively, if there is positive selection
for CCR5 use, successful transmission of R5X4 viruses may not occur because these
viruses uses CCR5 in a different manner than R5 viruses.
Numerous studies suggest that CCR5 use by R5X4 viruses differs from that of R5
viruses. CCR5 is a seven transmembrane protein with an N-terminus (NT) and three
extracellular loops (ECLs). The NT of CCR5 is modified by tyrosine sulfation, and
removal of sulfation within this domain by mutating tyrosine residues reduces infection
by R5X4 viruses more substantially than infection by R5 viruses (Farzan et al., 1999;
Rabut et al., 1998). Additionally, deleting amino acids from the NT of CCR5 has a larger
impact on infection by R5X4 compared to R5 viruses (Rucker et al., 1996; Yi et al.,
2003b). The ECLs of CCR5 are also critical domains for coreceptor function. Mutations
within the ECLs cause a greater decrease in CCR5-mediated infection by R5X4 versus
R5 viruses (Doranz et al., 1997; Genoud et al., 1999; Yi et al., 2003b). Inhibitors that
target this region within CCR5 also have differing effects on R5X4 and R5 viruses.
Antibodies with epitopes within the ECLs along with small molecule antagonists that
disrupt this domain typically inhibit R5X4 infection more than infection by R5 viruses
(Olson et al., 1999; Yi, Shaheen, and Collman, 2005). This suggests that, compared to
R5 viruses, R5X4 viruses have less efficient interactions with CCR5. However, neither
differences in the efficiency of Env-CCR5 interactions between R5X4 strains nor their
ramifications for coreceptor use on primary cells have been addressed.
Coreceptor use by HIV-1 is typically determined on cell lines that express CD4
and CCR5 or CXCR4 (Björndal et al., 1997; Deng et al., 1997). While these cell lines
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are invaluable tools for studying certain aspects of HIV-1 entry and infection, coreceptors
used on these cell lines may not accurately reflect coreceptor use on primary cells
(Collman, 1992; Tokunaga et al., 2001). Previous efforts by our lab to define the
coreceptors used by a small number of prototype R5X4 HIV-1 on primary cells revealed
these viruses can infect CD4+ macrophages using either CCR5 or CXCR4; however, in
CD4+ lymphocytes, CXCR4 was the predominate coreceptor used by R5X4 HIV-1 while
CCR5-mediated entry made only a marginal contribution to infection. In the same study,
R5 viruses readily infected CD4+ lymphocytes suggesting CCR5 use by R5X4 viruses is
severely impaired on these cells (Yi, Shaheen, and Collman, 2005). It is unclear how
widespread the impairment to lymphocyte CCR5 use is for R5X4 viruses, and what
factors regulate coreceptor use on primary lymphocytes. Given the selection for CCR5
use during transmission and the fact that CD4+ lymphocytes are likely the earliest cells
infected in an HIV-1 recipient, understanding the factors that regulate CCR5 use on
lymphocytes by R5X4 viruses may help elucidate why these viruses fail to establish
infections following transmission.

Goals of this thesis
The goal of this thesis is to better understand the patterns of coreceptor use by
R5X4 HIV-1 and to identify the factors that regulate CCR5 use on CD4+ lymphocytes by
this virus strain. In chapter 3, I determine the extent of CCR5 use on lymphocytes by a
panel of R5X4 HIV-1 viruses and examine the role of CCR5 expression on CCR5mediated infection of CD4+ lymphocytes by these viruses. My findings reveal a limited
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spectrum of lymphocyte CCR5 use by the R5X4 viruses in this panel that is determined,
in part, by low CCR5 expression. Increasing CCR5 levels on CD4+ lymphocytes
substantially increased CCR5-mediated entry by all but one virus, 89.6. In chapter 4, I
determine the efficiency of the Env-CCR5 interaction based on sensitivity to CCR5
antagonist, CCR5 antibody blocking and infection of a cell line that expresses inducercontrolled levels of CD4 and CCR5. I observed a significant correlation between greater
lymphocyte CCR5 use and both resistance to CCR5 blocking and reduced sensitivity to
changes in CCR5 expression. My results suggest viruses with greater lymphocyte CCR5
use have more efficient interactions with CCR5, which indicates this interaction is the
main determinant of CCR5 use on these cells. In chapter 5, I address the impact of
mutations within V3 on the efficiency of Env interaction with CCR5 and coreceptor use
by R5X4 HIV-1. My results show mutating an arginine at position 11 within the V3 of
89.6 to a serine increased the efficiency of interaction with CCR5 and changed coreceptor
use on CD4+ lymphocytes from preferential CXCR4 use to predominant CCR5-mediated
entry. Mutating this position resulted in 89.6 and C2-16 variants with altered use of the
CCR5 N-terminus. This indicates that V3, and position 306 in particular, is a principal
determinant of Env-CCR5 interactions and CCR5 use for some, but not all, R5X4
viruses. Thus, low CCR5 expression is a major obstacle to CCR5 use on lymphocytes by
R5X4 viruses, and the limited lymphocyte CCR5 use by R5X4 viruses is regulated by the
efficiency of the Env-CCR5 interaction. For most R5X4 viruses, the interaction is
inefficient resulting in poor lymphocyte CCR5 use; however, mutations that increase the
efficiency of this interaction can enhance CCR5-mediated infection of CD4+
lymphocytes.
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Chapter II - Materials and Methods
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Primary cells and cell lines
CD4+ lymphocytes were isolated by negative selection from whole blood (Stem
Cell Technologies, Vancouver, BC, Canada). Purified lymphocytes were maintained at
106 cells/ml in RPMI (Invitrogen, Carlsbad, CA) with 10% FBS (Thermo Scientific,
Waltham, MA) and stimulated for 3 days with 5 µg/ml of phytohemagglutinin (PHA; MP
Biomedical, Solon, OH) or in 24 well plates coated with 5 µg/ml of anti-CD3 (OKT3; a
gift of M. Betts, U. of Pa.) and anti-CD28 (clone 28.2; Beckman Coulter, Fullerton, CA)
antibodies. Cells were then either infected and maintained thereafter in IL-2, or cultured
for 10 days in IL-2 (300 U/ml; Proleukin, Novartis, Basel, Switzerland) to upregulate
CCR5 prior to infection. 293 Affinofile cells that express CCR5 and CD4 under
independent regulation were maintained in DMEM (Thermo Scientific) with 10%FBS,
blasticidin, G418, hygromycin and zeocin (Invitrogen) (Johnston et al., 2009; Lassen et
al., 2009). 293, U87/CD4, U87/CD4/CXCR4 and U87/CD4/CCR5 cells were obtained
from the NIH AIDS Research and Reference Reagent Program (Björndal et al., 1997;
Graham et al., 1977). 293 cells were maintained in DMEM with 10% FBS, and the U87
cell lines were maintained in selective media containing 1 µg/ml of puromycin (MP
Biomedical, Solon, OH) or 300 µg/ml of G418 (Invitrogen, Carlsbad, CA) for selection
of CD4 or CCR5 and CXCR4 respectively.

HIV-1 Env, CD4 and coreceptor expression vectors
HIV-1 R5X4 prototypes 89.6, DH12, and primary isolate NR Env clones were
derived from patients with advanced disease and have been previously described
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(Collman et al., 1992; Ray et al., 2007; Shibata et al., 1995). Env clone R3A was derived
from an unusual acute seroconverter found to harbor R5X4 variants during acute
infection, and it has been described previously (Meissner et al., 2004; Yu et al., 1998).
R5X4 variants C2 and DR were obtained from two HIV-infected CCR5-null individuals
homozygous for the ∆32 allele (Gray et al., 2006). The X4 isolate Tybe (from CSF) and
R5 strains JRFL (from brain) and Bal (from lung) have also been described previously
(Gartner et al., 1986; Koyanagi et al., 1987; Yi et al., 2003a). Prototype 89.6, R3A, JRFL
and Tybe Envs along with NR Envs were subcloned into the expression vector pCAGGS
(Niwa, Yamamura, and Miyazaki, 1991) using standard methods. The expression vectors
used to subclone the remaining vectors have been previously described (Helseth et al.,
1990; Kim et al., 2001). 89.6 and C2-16 envelope clones with mutations at position 11
within the V3 loop were generated using a Quick Change XL mutagenesis kit
(Stratagene, La Jolla, CA). NR Env clones were a gift from R. Doms (U. of Pa.), R3A
was obtained from J. Hoxie (U. of Pa.) and kindly provided by L. Su (UNC-Chapel Hill),
and JRFL, DH12 and Bal Env clones were generously provided by M. Cho (Case
Western Reserve).
CCR5 N-terminal deletion (Δ2-5, Δ2-9, and Δ2-13) mutant coreceptors were
kindly provided by R. Doms and have been previously described (Blanpain et al., 1999).
CCR5 N-terminal tyrosine (Y3A, Y10A, Y14A and Y15A) mutant coreceptors were
kindly provided by G. Leslie and J. Hoxie (U. of Pa.), and were created using the Quick
Change XL mutagenesis kit and sequence specific primers containing the appropriate
nucleotide substitutions. Coreceptors with these mutations have been described elsewhere
(Dragic et al., 2000; Genoud et al., 1999; Lee et al., 1999a; Siciliano et al., 1999)
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Pseudotype virus production
HIV-1 Env luciferase pseudotype viruses were generated by cotransfecting a
plasmid that expressed HIV-1 structural proteins (pCMVΔP1ΔenvpA), a plasmid that
expressed the packaged luciferase reporter (pHIV-1 luc), and an HIV-1 or VSV-G Env
plasmid. Plasmids were cotransfected into 293 cells using Fugene transfection reagent
(Roche, Palo Alto, CA) at ratios of 1:3:1 as previously described (Sterjovski et al., 2007;
Yang et al., 2004). GFP reporter viruses were created by cotransfection of structural
gene plasmid pHp1, GFP reporter plasmid pHRET-GFP, the tat expression plasmid
pCep4-tat, and a plasmid expressing an HIV-1 or VSV-G Env. Plasmids were
cotransfected into 293 cells at a ratio of 10:10:1:10 as previously described (Chang et al.,
1999). The CCR5 lentiviral expression vector pNL-CCR5 was created from pNL-CD4
by digestion with NotI and XhoI to remove CD4, and the CCR5 gene was amplified
(sense primer 5’-TAG TGC TGT TAA CTT GCT CAA TGC-3’ and antisense 5’-GAT
CAA GGA TAT CTT GTC TTC-3’) and subcloned into the NotI and XhoI sites. CCR5
transduction vectors were produced by cotransfecting pRev, pNL-CCR5 and pVSV-G
into 293 cells at a ratio of 1:2:1.
HIV-1 Env pseudotype viruses and lentiviral expression vectors were harvested
48 hours after transfection, clarified by centrifugation at 250xg, then stored in 5% sucrose
at -80°C until use. Plasmids pCMVΔP1ΔenvpA (Parolin et al., 1996) and pHIV-1-luc
(Yang et al., 2004) were generously provided by J. Sodroski (Harvard University), and
pNL-CD4 (Tokunaga et al., 2001) was kindly provided by B. Cullen (Duke University).
Plasmid pHRET-GFP (Lin et al., 2002) was provided by P. Corbeau (Hôpital Saint Eloi)
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and pHp1 and pCep4-tat (Chang et al., 1999) were a gift from J. Zucali (University of
Florida) obtained through the NIH AIDS Research and Reference Reagent Program.

CCR5 over-expression in CD4+ lymphocytes
PHA-stimulated CD4+ lymphocytes were pelleted (250xg at 25°C for 5 minutes)
and resuspended at 2x106 cells per ml in media containing 8 µg/ml of Polybrene. Cells
were then transduced using 200 µl of CCR5 expression vector pNL-CCR5, spin
inoculated for 2 hours as described (O'Doherty, Swiggard, and Malim, 2000), then
incubated in the presence of 10 U/ml of IL-2 at 37°C and 5% CO2 for 72 hours. After
this period, coreceptor expression was analyzed by FACS and cells were used for
infection.

Infection of cell lines and CD4+ lymphocytes
U87 cells were plated in 96 well plates at 1.5x104 cells per well one day prior to
infection, infected by spin inoculation at 1200xg for 2 hours with HIV-1 pseudotype
viruses (5 ng of p24 antigen per virus), and cultured at 37°C and 5% CO2 for three days.
For blocking studies, U87/CD4/CCR5 cells were pretreated for 1 hour and then infected
in the presence of 10 µg/ml of CCR5 mAb or serial dilutions of the CCR5 small molecule
antagonists. Luciferase activity was measured by lysing cells in PBS containing 0.1%
Triton X-100, combining cell lysate 1:1 with luciferase assay substrate (Luciferase Assay
System; Promega, Madison, WI) and measuring luciferase relative light units (RLUs)
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using a Dynex technologies microtiter plate luminometer. CCR5 monoclonal antibodies
2D7, 45531 and CTC8 were obtained from the NIH AIDS Research and Reference
Reagent Program, and mAb MC-1 (Blanpain et al., 2002) was a gift from M. Mack
(University of Munich). The CCR5 blocker M657 (Finke, 2000) was a gift from M.
Miller (Merck, W. Point, PA), and Maraviroc (Dorr et al., 2005) (Pfizer Inc., New York
City, NY) was obtained through the NIH AIDS Research and Reference Reagent
Program.
CCR5 wt and mutant coreceptor use was evaluated in 293 cells by plating cells in
6 well plates at 8x105 cells/well 24 hours before transfection. Cells were transfected
using Fugene transfection reagent with 1µg of a plasmid that expressed CD4 either alone
or in combination with 1µg of plasmid expressing wt or mutant CCR5. Cells were
washed twice with media the day after transfection, and 48 hours post transfection, cells
were removed with 2mM EDTA in PBS and replated either at 1.5x104 cells/well in 96
well plates for infection or at 8x105 cells/well in a 6 well plate for FACS. The following
day, cells were analyzed for CD4 and coreceptor expression as described below or
incubated with AMD3100 (1 µg/ml; Sigma-Aldrich, St. Louis, MO) for one hour then
infected with 5 ng of HIV pseudotypes by spinoculation as previously mentioned.
Infection levels were determined after 72 hours by lysing cells and measuring luciferase
activity in the cell lysates as detailed for U87 cells.
For infection of primary cells, PHA or CD3/CD28-stimulated CD4+ lymphocytes
were added to 96 well plates at 2x105 cells per well. Cells were pretreated for 1 hour
with saturating concentrations of CCR5 antagonists M657 (5 µg/ml) or Maraviroc (2
µM), the CXCR4 antagonist AMD3100 (5 µg/ml) or a combination of CCR5 and
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CXCR4 blockers. Following pretreatment, CD4+ lymphocytes were infected in the
presence of the inhibitors using an equal volume or 10 ng of p24 antigen per virus for
PHA or CD3/CD28-stimulated cells, respectively. CD4+ lymphocytes were infected by
spin inoculation at 1200xg for 2 hours, and then cultured at 37°C and 5% CO2 in the
presence of IL-2 for 3 days. Infection was measured by luciferase activity in the cell
lysate as previously described, or by FACS analysis of GFP expression.
Infection of 293 Affinofiles has been described in detail previously (Johnston et
al., 2009; Lassen et al., 2009). To briefly summarize, cells were plated at 1.5x104 cells
per well in 96 well plates in media containing 2% dialyzed FBS. Cell were allowed to
adhere for two days, then media was removed and replaced with media containing a fixed
concentration of the CD4-inducing reagent Minocycline (0.625 ng/ml) and varying
concentrations of the CCR5 inducer Ponasterone (0-2 µM). After an overnight
incubation, cells were pre-treated for at least 1 hour with 1 µg/ml of AMD3100 to block
CXCR4 in media containing 10% dialyzed FBS, then infected by spin inoculation using 1
ng of p24 antigen per luciferase pseudotype virus. Infected cells were cultured for 4 days
at 37°C and 5% CO2, after which luciferase activity was measured as described. FACS
analysis of CCR5 and CD4 expression was carried out the day of infection on cells that
were plated in 6 well plates and maintained in an identical manner.

FACS analysis of CD4, CCR5, CXCR4 and GFP expression
CD4+ lymphocytes were pelleted (250xg for 5 minutes), washed with FACS
buffer (PBS containing 1% fetal bovine serum and 0.1% NaN3), resuspended in 50 µl of
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FACS buffer and stained with 1 µl of mAbs to CD4 (clone RPAT-4- Fluorescein
isothiocyanate [FITC]-conjugated), CCR5 (clone 2D7-phycoerythrin [PE]-conjugated),
and CXCR4 (clone 12G-PE-Cy5-conjugated) (all from BD Biosciences, San Jose, CA).
Fluorescence minus one controls as well as cells stained with single antibodies were
carried out in parallel. Cells were incubated at room temperature in the dark for 30
minutes then washed and resuspended in FACS buffer at 106 cells per ml. Cells were
analyzed by a FACS Calibur flow cytometer (BD) using Cell Quest (BD) and FloJo
software (Tree Star Inc, Ashland, OR).
To determine the expression of CD4 and wt or mutant CCR5 on transfected 293
cells, cells were detached by incubation for 10 minutes in PBS containing 2mM EDTA,
pelleted, washed in FACS buffer then stained with CD4 FITC, CCR5 PE (clone 2D7) and
CCR5 (clone 3A9-Allophycocyanin [APC]-conjugated) as mentioned. Cells stained with
single antibodies were carried out in parallel, and fluorescence was measured and
analyzed as described. For CD4 and CCR5 quantification on 293 Affinofiles, cells were
detached as previously mentioned then stained with the CCR5 PE mAb or with CD4 PE
mAb (clone S3.5-Invitrogen, Carlsbad, CA) as described. Fluorescence was measured
and analyzed by FACS as described, and CD4 and CCR5 binding sites were quantified
using FloJo Software by comparing the average mean fluorescence intensity of stained
cells to a standard curve created using PE-labeled beads with four distinct, defined
quantities of fluorophores (QuantiBrite Beads, BD) as described (Davis et al., 1998). For
detection of GFP expression after CD4+ T cell infection by HIV-1 pseudotypes, cells
were washed and resuspended in FACS buffer as described 3 days post-infection and
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analyzed for GFP fluorescence using the FACS Calibur flow cytometer and FloJo
software.
Statistical analysis and PSSM matrix scoring
Statistical analysis was performed using GraphPad Prism 4 software. The EC50
values for M657 and Maraviroc were determined using a sigmoidal dose response
equation. Correlations were derived by linear regression analysis, and correlation
coefficients and p-values were determined using a 2-tailed Pearson test.
The predicted viral phenotype of R5X4 Envs used in this study was determined
using the position-specific scoring matrix (PSSM) program
(http://indra.mullins.microbiol.washington.edu/webpssm/). The PSSM algorithm
compares amino acids at each position within the V3 of submitted envelopes to the
corresponding residues from a database of Envs experimentally analyzed for coreceptor
use (R5/X4 matrix) or viral isolates tested for T cell line syncytium-inducing capacity
(SI/NSI matrix) as previously described (Jensen et al., 2003).
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Chapter III - Identification of the cellular factors that regulate CCR5
use on CD4+ lymphocytes by R5X4 HIV-1
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Introduction
Pathogenesis by R5X4 viruses is linked to CXCR4 use in several models.
Infection and depletion of lymphocytes in human lymphoid tissue infected ex vivo by
R5X4 HIV-1 is completely blocked by the CXCR4 antagonist AMD3100 (Glushakova et
al., 1999; Malkevitch et al., 2001). Moreover, infection of rhesus macaques with
SIV/HIV (SHIV) chimeras carrying R5X4 envelopes induces a disease course similar to
infection with X4 HIV-1 in humans (Nishimura et al., 2005; Nishimura et al., 2004). In
light of these findings, our lab attempted to define the coreceptors used on CD4+
lymphocytes by R5X4 HIV-1 in vitro using prototype viruses. Although infection was
quite robust on untreated lymphocytes, we were surprised to see almost no CCR5mediated infection of lymphocytes by prototype R5X4 viruses when CXCR4 was
blocked. Yet, R5 viruses used lymphocyte CCR5 for entry under the same conditions,
showing that R5X4 HIV-1 was severely impaired in the use of an otherwise functional
coreceptor. Conversely, when CCR5 was blocked, infection was not affected, indicating
that R5X4 HIV-1 entry into CD4+ lymphocytes occurred almost exclusively through
CXCR4 (Yi et al., 1999; Yi, Shaheen, and Collman, 2005). In contrast to those data,
other studies have suggested that lymphocyte CCR5 can be used by some R5X4 strains
(Ghezzi et al., 2001; Gray et al., 2006).
Thus, while CCR5 appears to be the secondary entry pathway into CD4+
lymphocytes by R5X4 HIV-1, it is unclear whether R5X4 viruses vary in their CCR5 use
and if entry mediated by this coreceptor can substantially contribute to T cell infection.
CCR5 expression is one factor that might regulate coreceptor use on CD4+ lymphocytes
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by R5X4 HIV-1. CCR5 is expressed at low density on a small percentage of CD4+
lymphocytes, and low levels of receptor expression in other cell types has been associated
with cell type-specific restriction of infection. Macrophages are poorly infected by many
lab-adapted X4 strains, but increasing CXCR4 expression increases macrophage
susceptibility to infection by these viruses (Tokunaga et al., 2001). Furthermore, studies
focused on coreceptor use by viruses from different tissues revealed that M-tropic R5
Envs were uncommon in blood, semen and lymph nodes. Interestingly, these Envs were
able to mediate infection of CD4+ lymphocytes at levels similar to M-tropic R5 Envs
recovered from brain. The lack of M-tropism by peripheral R5 Envs was associated with
an inability to infect cells expressing low levels of CD4 and CCR5 (Peters et al., 2004;
Peters et al., 2006).
In this chapter, I examine the diversity among R5X4 HIV-1 in the extent to which
CCR5 can be used for infection of lymphocytes, and identify factors that regulate
coreceptor use by these viruses on CD4+ lymphocytes. To do this, I assembled a diverse
panel of R5X4 envelope clones, determined the extent to which CCR5 contributed to
infection of CD4+ lymphocytes by pseudotyped luciferase reporter viruses, and examined
the effect of increasing CCR5 expression on lymphocyte coreceptor use. My findings
show a limited range of lymphocyte CCR5 use among the R5X4 viruses with some
viruses exhibiting extremely poor use of this coreceptor. Regardless of CCR5 use,
CXCR4 remained the predominant coreceptor used by all viral clones. I also found that
increasing CCR5 expression on lymphocytes could markedly enhance entry mediated by
this coreceptor for most (but not all) R5X4 viruses. Thus, low CCR5 expression on
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CD4+ lymphocytes is responsible for limiting and, in some cases, restricting CCR5mediated infection of T cells by R5X4 HIV-1 isolates.
Results
A spectrum of restricted CCR5-mediated entry into CD4+ lymphocytes exists among
R5X4 viruses
In order to examine the diversity in primary cell coreceptor utilization among
R5X4 HIV-1 and facilitate the identification of factors that influence primary cell
coreceptor use, we assembled a panel of diverse R5X4 env clones derived from divergent
sources. Luciferase reporter viruses were generated that carried primary isolate R5X4
HIV-1 envelope clones from three different infected individuals (DR, C2, NR), using
several individual Envs from within each swarm (Gorry et al., 2002b; Gray et al., 2006;
Ray et al., 2007). We also studied three widely used prototype R5X4 clones (89.6, DH12
and R3A) which are also primary isolate-derived (Collman et al., 1992; Meissner et al.,
2004; Shibata et al., 1995), along with control R5 and X4 Envs Bal and Tybe,
respectively (Hwang et al., 1991; Yi et al., 2003a). Of note, 89.6, DH12 and NR envs
were derived from late-stage AIDS patients (Collman et al., 1992; Ray et al., 2007;
Shibata et al., 1995), which is the most common situation in which these variants are
seen. R3A was an unusual R5X4 isolate in that is was obtained at the time of
seroconversion from an individual infected via intravenous drug use who exhibited rapid
disease progression (Meissner et al., 2004; Yu et al., 1998), whereas C2 and DR were
isolated from two CCR5-null individuals (Gray et al., 2006). Dual CCR5 and CXCR4
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Figure 3.1. Coreceptor use on U87 indicator cells by HIV-1 pseudotype viruses.
U87 indicator cells expressing only CD4, CD4 and CCR5, or CD4 and CXCR4 were infected with HIV-1
luciferase reporter viruses pseudotyped with primary isolate envelopes (C2, DR, NR), prototype R5X4
envelopes (89.6, DH12 or R3A), R5 (Bal or JRFL) or X4 envelopes (Tybe) as controls. Three days later,
infection levels were determined by measuring luciferase activity in cell lysates. The results are expressed
in relative light units (RLUs) and represent means +/- standard error (SEM) for two experiments performed
in triplicate.
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Figure 3.2. CXCR4 is the principal coreceptor on PHA/IL-2 stimulated CD4+ lymphocytes for R5X4
HIV-1 primary and prototype strains.
CD4+ T cells were stimulated with PHA for 3 days then treated for 1 hour before infection with or without
the CXCR4 blocker AMD3100 (5µg/ml; “CCR5 pathway”), CCR5 blocker M657 (5µM; “CXCR4
pathway”) or both (“neither pathway”). Cells were then infected with HIV-1 luciferase reporter viruses in
the continued presence of coreceptor blockers and maintained with IL-2 (10 U/ml). Four days post
infection, viral entry was determined by luciferase activity in cell lysates. Results shown for each virus are
presented in RLUs (A) and as a percentage of the RLUs seen in the absence of coreceptor blockers (B).
Data are means +/- SEM of three experiments using lymphocytes from different donors, each done in
duplicate.
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use for each virus was confirmed by infecting U87 cells that expressed CD4 and either
CCR5 or CXCR4 (Fig. 3.1).
In order to determine coreceptor use by these viruses on primary lymphocytes,
CD4+ T cells were infected in the absence or presence of CCR5 or CXCR4 antagonists
M657 and AMD3100, respectively (Fig. 3.2). As expected, Bal was completely inhibited
by the CCR5 antagonist M657 and Tybe by the CXCR4 antagonist AMD3100. When
CD4+ lymphocytes were infected with R5X4 pseudotypes, a different pattern was
evident. All R5X4 strains were markedly inhibited by CXCR4 blockade, whereas CCR5
blocking had no detectable effect. For all R5X4 strains, however, the addition of M657
to AMD3100 further reduced entry levels (Fig. 3.2a). These results indicate that all
R5X4 viruses tested entered CD4+ lymphocytes through both CXCR4 and CCR5, but
that infection through CCR5 was markedly less than that through CXCR4, and played
little, if any, additional role when both coreceptors were available.
To quantitate the relative contribution of each coreceptor to infection of CD4+
lymphocytes, the luciferase levels in the presence of coreceptor antagonists were
normalized to the total infection capacity for each virus in untreated cells (Fig. 3.2b).
Blocking CCR5 alone had no inhibitory effect on infection for any of the viruses.
However, CXCR4 blocking, when compared to dual coreceptor blocking, revealed
CCR5-mediated infection that ranged from ≤10% for the three prototype strains and two
of the DR primary isolate Envs, to 50% of untreated levels for the C2-16 primary isolate
Env. Thus, CXCR4 is the predominant coreceptor used by R5X4 viruses to infect CD4+
lymphocytes. However, some entry can be mediated by CCR5, and that proportion varies
between isolates indicating a spectrum of lymphocyte CCR5 use.
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Figure 3.3. CCR5 upregulation on CD4+ lymphocytes increases the proportion of R5X4 infection
mediated by CCR5.
CD4+ lymphocytes were CD3/CD28 costimulated for three days and then infected with HIV-1 luciferase
pseudotype viruses (A) or cultured with IL-2 for 10 additional days to upregulate CCR5 expression prior to
infection (B). Infections were carried out with or without AMD3100, M657 or both antagonists to block
CXCR4 and/or CCR5. Four days later, infection was determined by luciferase activity in cell lysates.
Entry was normalized as a percentage of the RLUs seen in the absence of coreceptor blockers for each
virus. Data are means +/- SEM of three experiments using lymphocytes from different donors, each done
in duplicate.
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CCR5 upregulation on CD4+ lymphocytes increases the proportion of R5X4 HIV-1 entry
mediated by CCR5
These data indicate that CCR5-mediated infection of CD4+ lymphocytes by many
R5X4 HIV-1 is restricted (Fig. 3.2), yet all viruses in question can use this coreceptor to
readily infect indicator cells such as U87 CD4/CCR5 cells (Fig. 3.1). CCR5 on indicator
cells is typically over-expressed, however, while peripheral blood lymphocytes express
CCR5 at low density and on a minority of cells (Lee et al., 1999b; Wu et al., 1997). We
therefore sought to test whether low levels of CCR5 expression were an obstacle to
efficient CCR5 use on CD4+ lymphocytes by R5X4 viruses, and how CCR5 expression
levels regulated pathway-specific R5X4 lymphocyte entry. To address the role of CCR5
expression, CD4+ lymphocytes were infected with HIV-1 luciferase pseudotype viruses
immediately after 3 days of CD3/CD28 costimulation, or after 10 additional days of
culture with 300 U/ml of IL-2, which has been shown to upregulate lymphocyte CCR5
(Creson et al., 1999; Yang et al., 2001). Infections were performed in the presence or
absence of CCR5 and CXCR4 antagonists to determine proportional use of each entry
pathway. Coreceptor expression as determined by surface staining indicated that few
CD4+ lymphocytes were CCR5+, whereas 20-40% had detectable CCR5 after prolonged
culture. In addition to the increase in percentage of cells within the CCR5+ gate, the
mean fluorescence intensity (MFI) of cells within the CCR5 gate increased as well
(approximately 2-fold). In contrast, the percentage of cells expressing CXCR4 decreased
to a modest degree but remained higher after culture with IL-2 (50-70%).
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As shown in Fig. 3.3a, CCR5 use by R5X4 HIV-1 was restricted in day 3
CD3/CD28-stimulated CD4+ lymphocytes, with CXCR4 being the predominant pathway
used for entry. However, there was a modest spectrum of CCR5 use similar to that seen
in PHA-stimulated lymphocytes (Fig. 3.2). In contrast, CCR5 upregulation following 10
days of IL-2 stimulation dramatically increased the proportion of infection mediated by
CCR5 for most R5X4 viruses tested, with the exception of 89.6, which remained nearly
completely CXCR4 dependent (Fig. 3.3b).
Nevertheless, for those viruses that did increase the proportion of entry mediated
by CCR5, CXCR4 remained the predominant coreceptor used for infection of day 13
CD4+ lymphocytes by most R5X4 strains. Exceptions to this coreceptor usage pattern
were seen in the two C2 Envs (C2-16 and C2-22) for which CCR5 consistently mediated
an equal or greater proportion of entry than did CXCR4 on CCR5-upregulated CD4+ T
cells (Fig. 3.3b). VSV-G pseudotypes, used as a control, showed no change in luciferase
expression from day 3 to day 13 cells (data not shown).

The percentage of CD4+ lymphocytes infected through each coreceptor is modulated
following CCR5 upregulation
In addition to total infection levels within the cultures, we also aimed to define the
contribution of each pathway to infection of individual CD4+ T lymphocytes following
CCR5 upregulation. CD4+ lymphocytes were cultured for 3 or 13 days as described
above to establish standard or high CCR5 expression conditions, respectively, and then
infected with HIV-1 Env pseudotype virions carrying a GFP reporter gene. Infection46

mediated GFP expression therefore enabled per-cell analysis of infection based on GFP
expression as determined by FACS. As with luciferase infection, addition of both CCR5
and CXCR4 antagonists completely blocked GFP expression (data not shown).
As shown in Fig. 3.4a, CCR5-mediated entry into day 3 CD4+ lymphocytes
resulted in a low percentage of GFP-positive infected cells. This value ranged from
barely detectable (DH12) to ~5% (C2-16 and the R5 Env JRFL). While this result is
concordant with the low percentage of cells positive for CCR5 expression by FACS, it
was interesting to note that the fraction of GFP+ cells for C2-16 and JRFL often
exceeded the proportion that were CCR5+ by FACS. Entry by these viruses was clearly
mediated by CCR5, however, since infection was blocked by M657 or Maraviroc (data
not shown). This finding indicates that susceptibility to infection by efficient CCR5using Envs can be a more sensitive indicator of CCR5 expression than immunostaining,
and thus, these isolates can use CCR5 at levels that are below the threshold of detection
by FACS. Furthermore, the fact that some strains can exploit CCR5 to infect what
appear to be CCR5-negative CD4+ T cells by FACS indicates that, following
upregulation, the apparent increases in percentage of CCR5+ cells also reflects increased
CCR5 expression levels by cells that are initially CCR5+ but at a level below the
threshold detectable by flow cytometry.
When CCR5 was upregulated on CD4+ lymphocytes by prolonged culture in IL-2
(Fig. 3.4a, right), the percentage of GFP+ cells infected through CCR5 increased
dramatically for the R5 isolate JRFL. Similarly, the percentage of GFP+ cells infected
through CCR5 also increased for R5X4 viruses following CCR5 upregulation, although
these percentages remained less than that for JRFL. Infection with VSV-G pseudotypes,
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Figure 3.4. Stimulation-dependent changes in coreceptor expression affect the percentage of CD4+
lymphocytes infected via each pathway.
CD4+ lymphocytes were infected with HIV-1 GFP pseudotype viruses after 3 days of CD3/CD28
costimulation or following an additional 10 days of culture with IL-2 to upregulate CCR5. Cells were
incubated with coreceptor antagonists for 1 hour prior to and throughout the infection to define the pathway
of entry. CCR5 and CXCR4 expression were analyzed by FACS on the day of infection, and four days
later, infected cells were determined by FACS analysis for GFP expression. Data indicate the percentage
of GFP+ cells infected through CCR5 (A) or CXCR4 (B) at day 3 and day 13 after isolation, and are
representative of three independent experiments using cells from different donors. The percentage of cells
expressing CCR5 (A) and CXCR4 (B) at the time of infection is indicated by an asterisk (*).
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used as a control for possible effects independent of coreceptor-mediated entry, showed
no change in infection (54±6% GFP+ on day 3 cells and 44±8% on day 13 cells; data not
shown). Thus, both R5X4 and R5 Envs are highly dependent on CCR5 expression levels,
although R5 JRFL is more efficient at exploiting limiting levels than R5X4 Envs (Fig.
3.4a).
In contrast to CCR5, CXCR4 levels typically decreased somewhat from day 3 to
day 13, and this was associated with a modest decrease in the percentage of cells infected
via CXCR4 for the R5X4 viruses tested, as well as the X4 strain Tybe (Fig. 3.4b).

Coreceptor-dependent R5X4 entry following lentiviral vector CCR5 over-expression
Although 10 days in culture with IL-2 upregulated CCR5 levels and modulated
coreceptor utilization, we considered the possibility that the extended period in vitro
could also effect other factors that impact infection, despite the lack of changes in VSVG pseudotype infection. For that reason, we used a second approach to upregulate CCR5.
CD4+ lymphocytes were transduced after 3 days of PHA stimulation with a lentiviral
vector expressing CCR5 or a mutated version of the coreceptor that is not expressed on
the cell surface. CCR5 levels on transduced cells were measured by FACS, and cells
were infected with prototype R5X4 Env luciferase viruses in the presence or absence of
AMD3100. Transduction with the CCR5 vector increased the proportion of CCR5+ cells
to 18-70% of CD4+ lymphocytes compared with 1-19% of cells transduced with a
control vector (Fig. 3.5), and the MFI of CCR5+ increased as well (fold increase of
2.9±0.9; data not shown). CCR5 over-expression led to a marked increase in entry
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mediated by CCR5 for R5X4 pseudotypes R3A and DH12 compared to control vectortransduced cells (Fig. 3.5). In contrast, entry mediated by CCR5 increased only
marginally for strain 89.6. CCR5 transduction had no impact on the MFI of CD4 or
CXCR4 expression and did not impact infection by the X4 virus Tybe (data not shown).
Results from the lentiviral vector CCR5 over-expression studies are similar to those
following stimulation-induced upregulation (Fig. 3.3), supporting the notion that entry as
measured here reflects changes in coreceptor expression and not other features of the cell
condition that might modulate infection.

50

Figure 3.5. Lentiviral over-expression of CCR5 increases the proportion of R5X4 entry mediated by
CCR5 on CD4+ lymphocytes.
CD4+ lymphocytes were stimulated with PHA for 3 days, transduced with either control or CCR5expressing lentiviruses, and maintained in the presence of IL-2. Two days post-transduction, cells were
pretreated for 1 hour with CXCR4 blocker AMD3100 and infected with HIV-1 luciferase pseudotypes in
the continued presence of blocker. Infection was determined by luciferase activity in cell lysates four days
later. The results are shown as the proportion of CD4+ lymphocyte infection mediated through CCR5 for
R3A (A), DH12 (B) and 89.6 (C) on the Y-axis, plotted against the percentage of CD4+ lymphocytes that
express CCR5 after transduction with a control or CCR5 expression vectors. Data are from three
independent experiments using cells from different donors.
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Conclusions
Coreceptor use and target cell tropism are important determinants of HIV-1
transmission and pathogenesis. In previous studies of primary cell tropism and
coreceptor use by prototype R5X4 HIV-1 strains, we found that these viruses could use
CCR5 and CXCR4 to infect macrophages, but in CD4+ lymphocytes, CXCR4 was the
predominant entry pathway while CCR5 was used poorly, if at all. Here I sought to
determine, employing a variety of dual-tropic isolates from disparate sources, whether
R5X4 strains vary in their ability to use CCR5 on lymphocytes, and what factors were
responsible for determining use of this pathway.
My findings reveal limited CCR5-mediated infection of CD4+ T cells by the
R5X4 strains tested, which did not substantially contribute to overall infection levels
when CXCR4 was available. However, a spectrum existed among the R5X4 variants in
the extent to which lymphocyte CCR5 could be used if CXCR4 was not available.
Notably, while one R5X4 virus could reach CCR5-mediated infection levels approaching
half that of untreated cells, R5X4 strains with marginal CCR5 use (≤ 10% of total entry)
were more common. CCR5 is expressed at low levels on CD4+ lymphocytes. My results
show that increasing CCR5 expression increased CCR5 use on CD4+ T cells by nearly
all viruses, including R5X4 strains that were among the most restricted in the use of this
coreceptor. However, 89.6 remained unable to use lymphocyte CCR5 even after
increasing CCR5 expression on these cells. Thus, we conclude that CCR5 expression on
CD4+ lymphocytes is an important regulator of the use of this coreceptor by many R5X4
viruses, but that other obstacles to lymphocyte CCR5 use may exist.

52

Even for R5X4 viruses with relatively greater lymphocyte CCR5 use, blocking
this pathway had no impact on CD4+ T cell infection, as entry through CXCR4 alone
was equivalent to infection when both coreceptors were available. CXCR4 is expressed
on the majority of peripheral blood CD4+ lymphocytes, whereas CCR5 is expressed on a
smaller subset of cells (Lee et al., 1999b; Ostrowski et al., 1998; van Rij et al., 2000; Wu
et al., 1997). Most cells that are CCR5+ also express CXCR4; so blocking CCR5 may
have little net effect on infection because entry can still occur through CXCR4.
Conversely, since many CXCR4+ lymphocytes do not express CCR5, entry in the
presence of CXCR4 blockers should be representative of the subset of cells that express
CCR5. As demonstrated by my findings following CCR5 upregulation, increasing the
subset of cells that express this coreceptor contributes to the increased proportion of
infection mediated by CCR5.
If CCR5 use was determined solely by the percentage of lymphocytes that express
this coreceptor, then CCR5-mediated infection should be equivalent for all R5X4 variants
(and should be equivalent to infection by R5 variants), yet that was not observed. CCR5
use on lymphocytes varied among the R5X4 viruses, and this variation appeared to be
related to the efficiency of interaction with CCR5. The percentage of lymphocytes
infected using CCR5 by C2-16, the R5X4 strain with the greatest CCR5 use, were higher
than the percentage of CCR5+ cells measured by FACS suggesting this virus can detect
CCR5 better than some CCR5 specific antibodies. Furthermore, the two R5X4 strains
with the greatest CCR5 use at endogenous levels were also the only viruses that showed a
shift in preferential coreceptor use to CCR5 after upregulation of this coreceptor. This
implies the R5X4 envs differ in the efficiency of interaction with CCR5 and the increased
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CCR5 density following CCR5 over-expression was a critical factor in the increased
CCR5-mediated infection of lymphocytes by R5X4 viruses. It is not clear from this
study if CCR5 density or the percentage of CCR5+ cells plays a larger role in regulating
use of this coreceptor on lymphocytes by R5X4 viruses.
The pattern of strain-dependent differences in the ability to use CCR5 on
lymphocytes also strongly suggests a role for Env in regulating use of this coreceptor on
lymphocytes by R5X4 viruses. Although CCR5 use by most of the viruses with
extremely poor use of this coreceptor could be improved by increasing CCR5 expression,
this was not the case for 89.6. Regardless of the method or magnitude of CCR5 overexpression, the virus remained extremely dependent on CXCR4 for infection. The nature
of restricted CCR5 use by this virus is unclear, but results following CCR5 upregulation
indicate CCR5 levels alone are not responsible for impaired lymphocyte CCR5 use by the
89.6 Env.
In summary, this study confirms with a panel of primary and prototype R5X4
HIV-1 variants that these strains are highly skewed towards CXCR4 use for entry into
CD4+ T cells. However, there does exist a range among the isolates in the relative ability
to use CCR5 on primary lymphocytes. CCR5 use by nearly all R5X4 viruses could be
improved by CCR5 over-expression in lymphocytes, and this was sufficient to eliminate
the barrier to CCR5 use for most, albeit not all, of the R5X4 isolates. These results
indicate low lymphocyte CCR5 expression is a factor in the restriction to R5X4 entry
through this pathway, although additional obstacles to primary cell coreceptor use exist.
Better understanding of the viral and cellular factors that control coreceptor use by HIV-1
strains is critical to understanding the impact of viral evolution on target cell tropism.
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Chapter IV - Efficiency of the Env-CCR5 interaction determines the
spectrum of CCR5 use on CD4+ lymphocytes by R5X4 HIV-1
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Introduction
HIV-1 Envs can differ in the ability to fuse viral and cellular membranes, and this
variation in entry efficiency can lead to differences in infectivity and pathogenicity
between viral strains. Longitudinal studies of HIV-1 infected patients that harbor only
R5 viruses show that isolates from advanced stages of disease replicate to higher titers
and are more cytopathic than isolates recovered during the asymptomatic phase of
infection. Subsequent experiments using chimeric viruses indicated that greater
infectivity of late R5 isolates was Env-dependent (Olivieri et al., 2007; Repits et al.,
2005). Animal models of HIV-1 infection also suggest links between entry efficiency
and pathogenesis. In vivo passage of SHIV-1 89.6 in rhesus macaques resulted in a
variant that aggressively depleted CD4+ lymphocytes and caused much more rapid
disease progression than infection with the parental virus (Karlsson et al., 1997). The
difference in pathogenicity between these variants was associated with higher levels of
replication on rhesus PBMCs and greater ability to induce syncytia by the passage virus.
In these studies, the phenotypic differences between the parental and passaged SHIV-1
were dependent on the viral Env (Karlsson et al., 1998).
Env-coreceptor interactions and receptor density both influence entry efficiency.
Changes in entry efficiency that result from differences in coreceptor binding or
coreceptor expression level can impact sensitivity to entry inhibitors. Indeed, mutations
that increase coreceptor binding and elevate CCR5 expression are both associated with
reduced sensitivity to entry inhibitors and faster rates of Env-dependent membrane fusion
(Heredia et al., 2007; Reeves et al., 2002). One study reported R5 Envs with lower
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CCR5 affinity require higher CCR5 levels for infection (Gorry et al., 2002a). This
observation implies that these two factors have an interdependent affect on viral entry,
and it suggests that increased coreceptor expression may enhance entry for viruses with
inefficient Env-coreceptor interactions.
R5X4 viruses are more sensitive to CCR5 antagonists than R5 viruses (Yi,
Shaheen, and Collman, 2005), and in chapter 3, I presented results that showed restricted
lymphocyte CCR5 use by R5X4 variants could be rescued by increasing CCR5
expression. These results imply that R5X4 viruses have inefficient interactions with
CCR5, and these interactions contribute to impaired lymphocyte CCR5 use by some
R5X4 viruses. I also observed a spectrum of CCR5 use by R5X4 strains on CD4+ T cells
at endogenous CCR5 levels. Differences in the Env-CCR5 interaction between R5X4
strains may also account for the range of lymphocyte CCR5 use seen among the viruses
in this group.
Therefore, in this chapter I examine the efficiency of the R5X4 HIV-1 Env
interaction with CCR5, and determine whether differences in this interaction influence
lymphocyte CCR5 use by these viruses. To do this, I measured the sensitivity of each
R5X4 virus to entry inhibition by antibodies, CCR5 antagonists and the fusion inhibitor
T20. Overall, my results show that R5X4 strains differed in their sensitivity to these
agents. Furthermore, I discovered a significant correlation between greater CCR5 use on
lymphocytes and increased resistance to inhibition by antibodies or antagonists; however,
there was no relationship between lymphocyte CCR5 use by R5X4 viruses and sensitivity
to T20. I also assessed the impact of CCR5 density on infection by various R5X4 strains
using Affinofile cells that allow inducible regulation of CCR5 expression. I found that
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R5X4 strains with greater lymphocyte CCR5 use were less affected by declining CCR5
levels. I also observed a significant positive correlation between the ability to exploit low
levels of CCR5 on the Affinofile cells and CCR5 use on lymphocytes. My results
indicate that the Env-CCR5 interactions regulate CCR5-mediated infection of
lymphocytes by R5X4 HIV-1, and strain-dependent differences in this interaction are
responsible for the spectrum of lymphocyte CCR5 use by the R5X4 virus panel.
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Results
Resistance to inhibition by ECL2-specific CCR5 mAbs correlates with the capacity of
R5X4 HIV-1 to use CCR5 for lymphocyte infection
Previous studies comparing CCR5 use by R5 and R5X4 Envs have suggested that
R5X4 Envs: i) appear to have a lower affinity for CCR5, ii) are generally more sensitive
to inhibition by CCR5 antagonists, and iii) are more affected by changes in the structure
of CCR5 (Cormier et al., 2000; Doranz et al., 1997; Lu et al., 1997; Yi, Shaheen, and
Collman, 2005; Yi et al., 2003b). Since R5 strains by definition use CCR5 efficiently for
lymphocyte entry, our finding that R5X4 strains vary in their capacity to infect primary
lymphocytes through CCR5 raised the possibility that these strains might also vary in
their interaction with CCR5.
To examine the relationship between Env-coreceptor interactions and lymphocyte
CCR5 use, we took advantage of CCR5-specific mAbs with well-characterized target
epitopes (Fig. 4.1) (Blanpain et al., 2002; Lee et al., 1999a). U87/CD4/CCR5 cells were
infected in the presence or absence of mAbs that target epitopes in the amino terminus
(N-terminal), the second extracellular loop (ECL2) or multiple domains (MD) of CCR5,
and entry inhibition was determined by normalizing infection levels to those of untreated
cells. As shown in Fig. 4.2, both mAbs that targeted CCR5 ECL2 (45531 and MC-1)
inhibited entry by the R5X4 viruses. Infection levels were reduced 15-70% by mAb
45531 and 30-90% by MC-1.

Treatment with 2D7, another ECL2-directed mAb,

completely inhibited infection by all viruses, even at four-fold lower concentrations (data
not shown). Importantly, R5X4 Envs that were better able to use lymphocyte CCR5 for
59

Figure 4.1. Antibody epitopes on CCR5.
The antibody binding sites for CCR5 antibodies CTC8 (red), 2D7 (blue), MC-1 (green) and 45531 (purple)
are shown within shaded squares. The epitope for multi-domain antibody 45523 is discontinuous and is not
shown.
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Figure 4.2. CCR5 use on CD4+ lymphocytes correlates with resistance to inhibition by ECL2 mAbs.
U87/CD4/CCR5 cells were treated for 1 hour with or without 10 µg/ml of CCR5-specific mAbs then
infected with HIV-1 luciferase pseudotype viruses in the continued presence of mAb. Three days later,
infection was determined by luciferase activity in cell lysates and normalized to luciferase activity in
untreated cells. Each symbol represents an individual R5X4 virus, and results are presented as the
proportion of total lymphocyte entry mediated by CCR5 (from Fig. 3.2b) on the X-axis versus the
U87/CD4/CCR5 infection that occurred in the presence of CCR5 mAbs (A) on the Y-axis. Data are means
for three experiments each carried out in duplicate.
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entry were blocked less efficiently than those viruses that used the pathway poorly, as
shown by the significant correlation between lymphocyte CCR5 use and infection in the
presence of ECL2-directed mAbs 45531 and MC-1 (Fig. 4.2). In contrast to the ECL2targeted antibodies, multidomain and N-terminal antibodies (45523 and CTC8,
respectively) had a marginal or no effect on entry (Fig. 4.2).

Sensitivity to CCR5 antagonists but not a fusion inhibitor correlates with lymphocyte
CCR5 use by R5X4 HIV-1
We then turned to small molecule CCR5 antagonists, which are frequently used as
probes to assess Env-coreceptor interactions. Sensitivity to CCR5 blockers M657 and
Maraviroc was determined by infecting U87/CD4/CCR5 cells in the presence of
increasing concentrations of inhibitor. Infection by all viruses was extinguished at the
highest concentrations of each antagonist (data not shown), but there was variation in
sensitivity to both M657 and Maraviroc, exemplified by differences in antagonist EC50
values among the R5X4 Envs (Fig. 4.3). M657 and Maraviroc EC50 values were lower
for R5X4 Envs with poor lymphocyte CCR5 use, compared to Envs such as C2-16 that
are better able to use this coreceptor. Similar to inhibition by ECL2-directed CCR5
mAbs, M657 and Maraviroc EC50 values correlated with lymphocyte CCR5 use (Fig.
4.3). Concordant mAb and antagonist results show a link between lymphocyte CCR5 use
and sensitivity to blocking among R5X4 HIV-1, and suggest that the variation in CCR5mediated infection of lymphocytes results at least in part from differences among these
strains in the efficiency of interactions with the coreceptor.
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Lymphocyte CCR5 use (% of total)
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T20
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Figure 4.3. CCR5 use on CD4+ lymphocytes correlates with resistance to inhibition by CCR5
antagonists but not T20.
U87/CD4/CCR5 cells were treated for 1 hour with or without increasing concentrations of M657 or
Maraviroc then infected with HIV-1 luciferase pseudotype viruses in the continued presence inhibitor. For
experiments with T20 increasing concentrations of the drug were added with virus at the time of infection.
Three days later, infection was determined by luciferase activity in cell lysates and normalized to luciferase
activity in untreated cells. Each symbol represents an individual R5X4 virus, and results are presented as
the proportion of total lymphocyte entry mediated by CCR5 (from Figure 3.2b) on the X-axis versus the
entry inhibitor EC50 value on the Y-axis. Data are means for three experiments each carried out in
duplicate.
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The fusion inhibitor T20 binds to the HR1 region of gp41 and prevents the
conformational changes that lead to membrane fusion. To determine whether R5X4
viruses differ in sensitivity to T20, U87/CD4/CCR5 cells were infected with HIV-1 in the
presence of increasing concentrations of drug. Infection by all viruses was inhibited at
the highest concentration of T20 (data not shown). While there was a range of T20 EC50
values that were similar for most viruses, DR-17 was substantially less sensitive to the
drug with an EC50 value that was over two logs higher than the median EC50 value of
the group (data not shown). Consequently, this virus was excluded from subsequent
analysis. Unlike the CCR5 antagonists, viruses with greater lymphocyte CCR5 use were
not less sensitive to inhibition by T20, and there was no correlation between T20 EC50
value and CCR5 use on lymphocytes by R5X4 viruses (Fig. 4.3). Thus, differences in
the efficiency of fusion do not appear to impact lymphocyte CCR5 use by R5X4 viruses.
Greater lymphocyte CCR5 use is associated with reduced sensitivity to CCR5 density for
infection of Affinofile cells
Increasing CCR5 expression on CD4+ lymphocytes increased the proportion of
infection mediated by CCR5 for R5X4 viruses, suggesting inefficient use of endogenous
CCR5 might be linked to sensitivity to coreceptor expression levels. To further address
the interplay between CCR5 expression and R5X4 infection, we used 293 Affinofile cells
(Fig. 4.4), a cell line in which expression of CD4 and CCR5 can be regulated precisely
and independently by Minocycline and Ponasterone, respectively (Johnston et al., 2009;
Lassen et al., 2009). The number of CD4 and CCR5 antibody binding sites (ABS) per
cell can be determined for each inducer combination using quantitative FACS analysis.
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Figure 4.4. Inducible CD4 and CCR5 Affinofile expression system.
Affinofile cells were created by transfecting 293 cells with plasmids expressing CD4 and CCR5 along with
separate plasmids expressing inducible transcription factors that are responsive to minocycline and
ponasterone. Addition of increasing concentrations of minocycline or ponasterone increases CD4 or CCR5
expression, respectively (A). Addition of different combinations of each inducer allows independent
regulation of CD4 or CCR5 levels, which can be quantitated by FACS (B). Figure courtesy of Johnston, S.
et al. J. Viro. 2010
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Induction of Affinofile cells resulted in CD4 expression levels that ranged from 3,000 to
200,000 ABS per cell and CCR5 levels from 1,000 to 50,000 ABS per cell. Importantly,
these levels encompass the physiologically relevant range of CD4 and CCR5 levels
reported on stimulated CD4+ lymphocytes of 65,000-100,000 and 500-7,000 molecules
per cell, respectively (Lee et al., 1999b). Therefore, we chose to examine the sensitivity
of R5X4 HIV-1 infection to CCR5 expression levels in Affinofile indicator cells by
analyzing the effect of physiologically relevant CD4 expression levels (~83,000
molecules/cell). Cells were maintained with a stable concentration of CD4 inducer and
different concentrations of CCR5 inducer, and infected with luciferase pseudotype
viruses at the same time that receptor expression levels were confirmed by FACS.
Luciferase levels produced at each CCR5 density were normalized to luciferase activity
in cells with the highest density of CCR5.
As shown in Fig. 4.5a, at a stable level of CD4 expression, luciferase virus
infection was reduced for all R5X4 viruses as CCR5 density decreased. However, there
were marked differences in the response to declining CCR5 levels. R5X4 Envs C2-16
and NR10 were least affected by declining CCR5 expression, showing 60 to 80% of
maximal infection even at the lowest CCR5 density. A second group of R5X4 viruses,
R3A, DR17 and DH12, were more impaired by low CCR5 expression, achieving 35-45%
of maximal infection at the lowest CCR5 expression level tested. 89.6 was the R5X4
virus most affected by decreasing CCR5 expression, at the lowest density of CCR5
expression reaching only 25% of its maximal level of infection (Fig. 4.5a). Thus, R5X4
HIV-1 display a spectrum in their ability to use diminishing levels of CCR5 on Affinofile
cells in the presence of physiologically relevant CD4 levels.
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Rsq = 0.9437
p < 0.005

Figure 4.5. Efficiency of CCR5 use on Affinofile cells correlates with CCR5 use on CD4+
lymphocytes by R5X4 HIV-1.
Affinofile cells were induced to express a fixed level of CD4 (83,000 antibody binding sites (ABS)/cell)
and varying levels of CCR5, then infected with HIV-1 luciferase pseudotypes in the presence of AMD3100
to block endogenous CXCR4. Infection was quantified 4 days later by luciferase activity in cell lysates.
The results are shown as the luciferase levels at each CCR5 density normalized to infection levels on cells
expressing the maximum density of CCR5 (A). The relationship between normalized infection of Affinofile
cells expressing the lowest density of CCR5 and the proportion of total CD4+ lymphocyte infection that is
mediated by CCR5 (from Fig. 3.2b) for each R5X4 Env pseudotype is also shown (B).
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Ability to use CCR5 on CD4+ lymphocytes by R5X4 HIV-1 correlates with the use of low
levels of CCR5 on 293 Affinofile cells
We then asked if there was an association between R5X4 use of lymphocyte
CCR5 and entry into Affinofile cells expressing CCR5 at the lowest density (Fig. 4.5a).
Overall, there was a strong correlation for R5X4 HIV-1 between the proportion of CD4+
lymphocyte entry mediated by CCR5 and the ability to infect Affinofile cells expressing
diminishing levels of CCR5 (Fig. 4.5b). C2-16 and NR-10 used CCR5 on lymphocytes
more efficiently than other R5X4 viruses and were least sensitive to decreasing levels of
CCR5 on the Affinofile cells. Lymphocyte CCR5 use was lowest for 89.6 and infection
of Affinofile cells was most impaired by decreasing CCR5 levels for this virus. DR17,
R3A and DH12 showed an intermediate phenotype in both lymphocyte CCR5 use and
infection of Affinofile cells expressing low levels of CCR5. These results confirm that
there is biological heterogeneity among R5X4 HIV-1, and suggest that strains with
marginal CCR5 use on lymphocytes are unable to effectively scavenge for CCR5 when it
is expressed at low density.
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Conclusions
Entry efficiency, which is dependent on Env-coreceptor interactions and
coreceptor density on target cells, is an important determinant of replication capacity and
pathogenesis. Previous work from our lab showed that R5X4 viruses were more sensitive
to CCR5 antagonists than R5 viruses, and in chapter 3, I described how increasing CCR5
expression on CD4+ lymphocytes enhanced CCR5 use by viruses with poor use of this
coreceptor. Thus, previous reports combined with my recent findings suggested
inefficient Env-CCR5 interactions may be one mechanism that regulates lymphocyte
CCR5 use by R5X4 strains.
In this chapter, I determined the relationship between the efficiency of CCR5 use
by R5X4 strains and lymphocyte CCR5 use. Using sensitivity to entry blocking agents as
a surrogate marker for the efficiency of CCR5 use, I found that R5X4 viruses were
markedly inhibited by CCR5 antibodies with ECL2 epitopes but not by other CCR5
antibodies, and resistance to inhibition correlated with greater lymphocyte CCR5 use. In
addition, I found a significant correlation between greater lymphocyte CCR5 use by
R5X4 strains and resistance to inhibition by CCR5 antagonists, but not the fusion
inhibitor T20. I also employed Affinofile cells with regulated levels of CD4 and CCR5
to examine the impact of CCR5 expression on infection by R5X4 strains. I discovered
that decreasing CCR5 expression had the largest impact on infection by viruses that used
lymphocyte CCR5 poorly, in that strains with greater lymphocyte CCR5 use could better
exploit low levels of CCR5 on these cells. From these results, I conclude that the
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spectrum of lymphocyte CCR5 use by R5X4 HIV-1 is determined by the efficiency of the
Env-CCR5 interaction.
CCR5-mediated infection of CD4+ lymphocytes by R5X4 HIV-1 is relatively
small in comparison to infection mediated by CXCR4 when that coreceptor is available,
but the levels of lymphocyte CCR5 use vary among the R5X4 strains. The results
outlined here indicate the efficiency of the Env-CCR5 interaction differs between viruses
and is a principal determinant of the ability to use this coreceptor. Specifically, viruses
with more efficient Env-coreceptor interactions are able to use low levels of CCR5 more
efficiently, suggesting that these viruses require a lower threshold of CCR5 to facilitate
membrane fusion. The density of CCR5 expressed on individual CD4+ lymphocytes
varies (Reynes et al., 2000), and these findings indicate that R5X4 strains with a lower
CCR5 density threshold can reach higher levels of infection by infecting lymphocytes
that express minimal levels of CCR5. Thus, the percentage of CCR5+ CD4+
lymphocytes determines the potential levels of CCR5 use, but actual CCR5 use by an
R5X4 variant is determined by how efficiently its Env interacts with the coreceptor.
The results of this study show that CCR5 mAbs with epitopes in ECL2 inhibit
R5X4 infection, and the extent of this inhibition is associated with the ability to use
CCR5 on lymphocytes. This suggests the efficiency of interaction with ECL2 contributes
to determining lymphocyte CCR5 use by R5X4 strains. On the other hand, it is also
possible that these mAbs are affecting interactions with other CCR5 domains, since
inhibition by an antibody is not always dependent on competition for the epitope. For
example 2D7 effectively blocks CCR5 use by R5 and R5X4 strains, yet in two studies,
mutation of the CCR5 2D7 binding site had no impact on CCR5 use (Rabut et al., 1998;
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Siciliano et al., 1999), indicating the 2D7 epitope itself is not required for infection by
HIV-1. It has been proposed that 2D7 inhibits HIV-1 infection by blocking access to
critical residues in the transmembrane core of CCR5 (Siciliano et al., 1999). The results
presented in this chapter do appear to show a relationship between the proximity of an
antibody epitope to the CCR5 core and the ability of that antibody to inhibit infection,
although only a limited number of antibodies were used. Thus, these findings suggest the
interactions with the ECLs, or possibly other residues near this region, make a significant
contribution to regulating the efficiency of CCR5 use.
It is interesting that sensitivity to CCR5 antagonists correlated with lymphocyte
CCR5 use but not sensitivity to the fusion inhibitor T20. CCR5 antagonists are allosteric
inhibitors that are thought to prevent HIV-1 infection by binding within the pocket
created by the extra cellular loops and altering the conformation of the coreceptor (Dragic
et al., 2000). T20 is a steric inhibitor that binds to HR1 in gp41 and prevents formation
of the 6-helix bundle that is required for membrane fusion (Rimsky, Shugars, and
Matthews, 1998; Wild, Greenwell, and Matthews, 1993). Mutations in the coreceptor
binding site that reduce Env binding invariably increase sensitivity to coreceptor
antagonists, but the same mutations do not always have a similar effect on T20 sensitivity
(Biscone et al., 2006; Reeves et al., 2002; Reeves et al., 2004). From these relationships,
it appears that efficiency of the Env-coreceptor interaction may not be inextricably linked
to the efficiency of the subsequent conformational changes in gp41. This also implies
that sensitivity to coreceptor antagonists measures the efficiency of a single step in the
fusion process. In light of that possibility, my findings suggest that Envs with more

71

efficient interactions with CCR5 likely have a higher affinity for the coreceptor, although
this would have to determined by measuring affinity for CCR5.
The findings in this study indicate that R5X4 strains vary in the efficiency of
interaction with CCR5, and the variation in Env-CCR5 interaction efficiency impacts
coreceptor use on primary lymphocytes. Specifically, R5X4 HIV-1 with more efficient
Env-CCR5 interactions infect CD4+ lymphocytes using CCR5 at much higher levels than
viruses with inefficient interactions with the coreceptor. I also discovered that this
variation in Env-CCR5 interaction may be, at least in part, determined by interactions
with ECLs or residues proximal to this region, based on sensitivity to ECL2 antibodies
and coreceptor antagonists.
Notably, 89.6, the virus with the least efficient interactions with CCR5, is also the
virus that failed to respond to increased CCR5 expression on CD4+ lymphocytes in
chapter 1. The barrier to CCR5 use by this strain and the factors in Env that regulate
primary cell coreceptor usage and preference have not been identified, but this field
necessitates further study if we are to fully understand pathogenesis by R5X4 HIV-1.
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Chapter V - Molecular determinants within Env that regulate
coreceptor use on CD4+ lymphocytes

73

Introduction
The spectrum of lymphocyte CCR5 use by the R5X4 viruses studied here is
dependent on the efficiency of the Env-coreceptor interaction, and variation in this
interaction is Env-dependent. Although many domains in Env influence interactions with
coreceptor, the V3 domain is the primary determinant of coreceptor use, and it is thought
to directly interact with the coreceptor (Choe et al., 1996; Cormier and Dragic, 2002;
Cormier et al., 2000). The V3 domain is also a critical determinant of viral phenotype.
In CXCR4/CD4+ T cell lines, X4 and R5X4 viruses are able to induce syncytia (SI
variants) while R5 strains are nonsyncytium inducing (NSI) in these cells (Björndal et al.,
1997). This phenotypic difference between strains is based on coreceptor use and is
largely determined by the V3 domain (Björndal et al., 1997; de Jong et al., 1992b).
Comparative analysis of the V3 sequence of HIV-1 viruses with distinct phenotypes has
led to the identification of features within this domain that are linked to use of CCR5 or
CXCR4. As outlined in chapter 1, a high net positive charge and the presence of
positively charged amino acids at positions 11 and 24 or 25 (positions 306 and 319 or 320
using HXB2 Env numbering) are well-known features associated with CXCR4 use by
HIV-1 (Cardozo et al., 2007; Fouchier et al., 1992; Milich, Margolin, and Swanstrom,
1993). Several position specific scoring matrices (PSSM) have been developed to predict
coreceptor use from V3 sequences based on large databases of viruses characterized as
R5 vs X4 (X4/R5 PSSM) or NSI vs SI (SI/NSI PSSM) (Jensen et al., 2003). The
presence of these specific features within V3 and the related PSSM algorithm distinguish
X4 from R5 viruses with reasonably high although imperfect accuracy; however, the V3
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of R5X4 strains are more varied and do not always conform to this paradigm. Presently,
it is unclear how variability in V3 relates to coreceptor use by R5X4 viruses, particularly
on primary CD4+ lymphocytes.
The spectrum of lymphocyte CCR5 use by R5X4 strains includes variants with
marginal use of this coreceptor, such as 89.6. Unlike the other R5X4 viruses in this
category, increased CCR5 expression on CD4+ lymphocytes did not enhance CCR5 use
by 89.6, and severely impaired lymphocyte CCR5 use by this virus correlated with
inefficient interactions with CCR5 by a number of different measures. These findings
together suggest restricted CCR5 use by 89.6 is dependent on the viral Env.
Determinants within the 89.6 Env that impact coreceptor use have been identified in V3.
Deletions on either side of the 89.6 Env V3 base abrogate CCR5 use, while deleting a
section of stem that contains residue 306 abolished CXCR4 use by this virus (Nolan,
Jordan, and Hoxie, 2008). Another study attempted to derive variants of 89.6 resistant to
CXCR4 inhibitors on cell lines expressing both coreceptors and identified a change from
arginine to serine at position 306 that conferred resistance through enhanced CCR5 use
(Maeda, Yusa, and Harada, 2008). A recent study of other R5X4 viruses also suggests a
role for amino acid 306 in modulating coreceptor use. The efficiency of CCR5 and
CXCR4 use on primary cells for brain versus blood or spleen-derived R5X4 envelopes
was linked to the presence of a serine or arginine, respectively, at position 306 in V3
(Gray et al., 2009). Thus, residue 306 within Env appears to be a critical determinant of
coreceptor use for 89.6 and for other R5X4 viruses, but it is not known whether the
amino acid at this position contributes to restricted lymphocyte CCR5 use by 89.6 or the
spectrum of lymphocyte CCR5 use by the other R5X4 viruses.
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The goals of this chapter are to assess whether elements in V3 regulate
lymphocyte CCR5 use by R5X4 viruses, and to identify determinants in the 89.6 Env that
are responsible for the severely impaired lymphocyte CCR5 use by this virus. To do this,
the viral phenotype of each R5X4 virus was predicted using a V3-based position-specific
scoring matrices (PSSM)-algorithm, and the relationship between predicted phenotype
and lymphocyte CCR5 use by R5X4 viruses was evaluated. Eventhough all strains tested
were R5X4 in indicator cells, I found that those with greater lymphocyte CCR5 use were
predicted to be NSI viruses, while viruses with poor lymphocyte CCR5 use were
predicted to be SI viruses. To determine the factors within the 89.6 Env that regulate
lymphocyte CCR5 use, I mutated R306 in 89.6 to serine (89.6 R306S). In addition, the
role of this residue in regulating coreceptor use by other R5X4 viruses was assessed by
mutating the same residue in C2-16, the R5X4 Env with greatest lymphocyte CCR5 use,
from serine to arginine (C2-16 S306R). I found that an arginine at this position was
associated with increased sensitivity to CCR5 blocking agents for both 89.6 and C2-16.
Moreover, viruses with an arginine at residue 306 were more dependent on the Nterminus of CCR5 for infection. My results also show the presence of a serine at position
306 dramatically enhanced CCR5 mediated infection of CD4+ lymphocytes by 89.6, and
switched coreceptor preference from CXCR4 to CCR5 on these cells. However, arginine
at this position had no impact on lymphocyte coreceptor use by C2-16. Thus, the amino
acid at position 306 regulates interactions with CCR5 for 89.6 and C2-16; it also
regulates coreceptor use on primary lymphocytes by 89.6.
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Results
Relationship between V3 sequences and CD4+ lymphocyte coreceptor preference
The V3 region is a major determinant of coreceptor use, and position-specific
scoring matrix (PSSM) algorithms based on variations in this domain are frequently used
to predict viral phenotype. Two widely used algorithms are based on viruses phenotyped
by syncytia induction in CXCR4/CD4+ cell lines (SI/NSI PSSM) or on coreceptor use in
indicator cells (X4/R5 PSSM), which are highly related although not completely
concordant features (Jensen et al., 2003). However, such algorithms are typically less
able to identify dual-tropic R5X4 than single coreceptor R5 and X4 variants. More
importantly, while used for indicator cell coreceptor use prediction, they have not been
applied to selective use of coreceptors on primary cells. Therefore, we applied the PSSM
algorithms to V3 sequences from Envs in our panel to determine whether primary CD4+
T cell coreceptor usage among R5X4 HIV-1 might be associated with sequences in V3
(Fig. 5.1a). Strikingly, we found that prediction of an NSI phenotype based on V3
sequence was associated with significantly more efficient use of lymphocyte CCR5 (Fig.
5.1a & b). Conversely, R5X4 viruses with more restricted entry through lymphocyte
CCR5 were predicted to be SI. Thus, while unable to identify these R5X4 strains as a
group, the SI/NSI algorithm appears to discriminate among R5X4 strains and predict
relative efficiency of lymphocyte CCR5 use based on V3 determinants. In contrast, there
was no link between primary lymphocyte coreceptor usage and predicted coreceptor
phenotype based on V3 sequences using the X4/R5 coreceptor prediction algorithm.
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Figure 5.1. R5X4 HIV-1 CCR5 use on CD4+ lymphocytes is associated with the predicted viral
phenotype.
V3 sequences from each virus were analyzed using the NSI/SI or X4/R5 PSSM algorithm. The table shows
an alignment of V3 sequence from R5X4 HIV-1. Amino acids 11 (306) and 24/25 (319/320) are denoted in
bold. The coreceptor use on primary lymphocytes for each R5X4 virus is shown (from Fig. 3.2). Predicted
phenotypes are denoted by number with 1=SI or X4 and 0=NSI or R5 (A). Mean CCR5 use on CD4+
lymphocytes by R5X4 HIV-1 grouped by predicted viral phenotype. R5X4 viruses were grouped by SI or
NSI phenotype from (A) with CCR5 use for each virus represented by black circles. The mean lymphocyte
CCR5 use for each group was calculated, and the means were compared using a two-tailed, unpaired t-test
in GraphPad Prism 4 software (***p<0.0001) (B).
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Interestingly, most of these R5X4 Envs were predicted to be R5 by the X4/R5 PSSM
matrix, which differed from the SI/NSI algorithm results. Thus, while the V3-based
PSSM is an incomplete predictor of coreceptor use for R5X4 strains, it does appear to
predict the relative coreceptor preference on lymphocytes suggesting an important role of
V3 in regulating coreceptor interactions.
A high net positive charge and positively charged amino acids at position 306 and
319/320 of V3 are typically associated with CXCR4 use, whereas R5 strains typically
lack these determinants. R5X4 strains can use CXCR4, but these viruses often lack many
of the features common in the V3 of X4 strains. However, variability in V3, including
the presence or absence of hallmarks of CXCR4 use, may be associated with coreceptor
use on primary lymphocytes by R5X4 strains. To assess this, the V3 net charge, as well
as the identity of the amino acids at positions 306 and 319/320, were evaluated to
determine if they were linked to CCR5 use on CD4+ T cells by the R5X4 viruses (Fig.
5.1a). This analysis revealed most of R5X4 strains in this panel have V3 charges that are
only slightly higher than the R5 strain, Bal. Positively charged amino acids were
uncommon at residues 306 or 319/320, and there was no consistent connection between
positive charges at these positions and lymphocyte CCR5 use by the R5X4 viruses.
Interestingly, while the spectrum of CCR5 use could not be defined by the residues at 306
and 319/320 or the V3 net charge, the viruses on both extremes of the CCR5-use
spectrum did adhere to these rules. C2-16 and C2-22, the viruses with the greatest CCR5
use on lymphocytes, had net positive charges equal to Bal, and these viruses did not have
basic residues at either V3 stem position. Alternatively, 89.6, which had the poorest use
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Figure 5.2. The amino acid at position 306 in Env does not affect coreceptor use on U87 cells by 89.6
or C2-16.
The amino acids of envelope V3 regions of 89.6 and C2-16 are shown, along with the 89.6 R306S and C216 S306R mutations, which correspond to position 11 of the V3 domain (A). U87/CD4, U87/CD4/CCR5
and U87/CD4/CXCR4 were infected with wild-type and mutant 89.6 and C2-16 luciferase pseudotype
viruses. The results are presented as the RLUs measured from cell lysates 3 days after infection (B).
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of lymphocyte CCR5, had a much higher V3 charge than any other R5X4 strain, and it
was the only clone with basic amino acids at both positions 306 and 319 in this study.
This result also suggests that elements within V3 contribute to regulation of coreceptor
use by R5X4 viruses on lymphocytes.

R306 is associated with increased sensitivity to inhibition by 2D7 and Maraviroc and less
efficient interactions with CCR5
While CCR5 use on CD4+ lymphocytes by R5X4 envelopes was bolstered by
increasing CCR5 expression, this measure had little effect on lymphocyte CCR5 use by
89.6. Therefore, for this virus, we wished to address the Env side of the Env-CCR5
interaction by determining if specific changes within V3 might alter the efficiency of
CCR5 use and affect lymphocyte entry. I speculated that the amino acid at position 306
within Env might be involved in determining the efficiency of 89.6 Env-CCR5
interaction, since several studies have shown that this residue can influence coreceptor
use for 89.6 and other R5X4 strains (Gray et al., 2009; Maeda, Yusa, and Harada, 2008;
Nolan, Jordan, and Hoxie, 2008). To test this notion, R306 in 89.6 was mutated to serine
(89.6 R306S; Fig. 5.2a). In contrast to 89.6, the R5X4 Env with greatest lymphocyte
CCR5 use, C2-16, has a serine at position 11 in V3. Therefore, we also mutated the
serine at this position in C2-16 to arginine in order to assess the converse effect (C2-16
S306R) (Fig. 5.2a). Both Envs remained R5X4 in U87/CD4/coreceptor cells (Fig. 5.2b).
Sensitivity to CCR5 antagonists and mAbs are one method used to probe Env-coreceptor
interactions, so I employed these inhibitors to determine whether mutations at residue
306 within the 89.6 and C2-16 V3 domains had an effect on interactions with CCR5.
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Figure 5.3. Residue R306 in Env is associated with less efficient interactions with CCR5.
U87/CD4/CCR5 cells were not treated or pretreated with increasing concentrations of Maraviroc (A) or
2D7 (B), then infected with wt and mutant 89.6 and C2-16 in the continued presence of blocker. Results
are presented as the luciferase activity in the presence of drug normalized to luciferase activity in the cell
lysate of untreated cells. Affinofile cells expressing a fixed level of CD4 and differing levels of CCR5
were infected with wild-type and mutant 89.6 and C2-16 luciferase pseudotype viruses. The results are
shown as the luciferase levels at each CCR5 density normalized to infection levels on cells expressing the
maximum density of CCR5 (C).
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Infection of U87 cells by wt and mutant 89.6 and C2-16 was inhibited at the highest
Maraviroc concentrations (Fig. 5.3a). As seen in earlier studies, wt 89.6 was
substantially more sensitive to inhibition by Maraviroc than wt C2-16, which required
approximately one log higher concentration of the drug to completely inhibit entry. The
R306S mutation in 89.6 resulted in a decrease in sensitivity to Maraviroc, while the
S306R mutation in C2-16 increased sensitivity to this CCR5 antagonist (Fig. 5.3a).
Infection of U87 cells in the presence of mAb 2D7 resulted in a similar inhibition pattern,
with wt 89.6 and C2-16 being the most and least sensitive to inhibition by the mAb,
respectively (Fig. 5.3b). The 89.6 mutant R306S showed reduced sensitivity to 2D7
compared to wt 89.6, and the reciprocal S306R mutation in C2-16 lead to increased 2D7
sensitivity for this virus relative to wt C2-16. These findings suggest that the residue at
position 306 in Env modulates Env-CCR5 interactions. In particular, the presence of
arginine at residue 306 decreases the efficiency of the Env-CCR5 interaction while serine
at this position enhances interaction.
The changes in sensitivity to CCR5 blockers caused by mutations at position 306
suggested that the identity of the amino acid at this position could also impact how
efficiently viruses used CCR5 to infect target cells. To address this question, we infected
293 Affinofiles expressing a fixed level of CD4 and varying levels of CCR5 to test the
effect of the Env mutations on the efficiency of CCR5 use in that system. As noted in
chapter 4, infection by 89.6 decreased markedly as CCR5 density on Affinofiles dropped
from maximal to minimal levels. Replacing the arginine at position 306 with serine
resulted in a two-fold enhancement of entry at the lowest CCR5 levels, reaching a
relative entry efficiency comparable to that for C2-16 (Fig. 5.3c). In contrast, the C2-16
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S306R mutation had some effect on entry efficiency at intermediate CCR5 levels, but not
at the lowest CCR5 density; which most closely mimics those on primary CD4+
lymphocytes (Fig. 5.3c).

Impaired CCR5 use on CD4+ lymphocytes by 89.6 is reversed by the R306S mutation
within the V3 region
Since residue 306 modulates the efficiency of CCR5 use, it might also regulate
the ability or inability of 89.6 to use CCR5 on lymphocytes. This question was addressed
by evaluating coreceptor use on primary CD4+ T cells by wild type and mutant 89.6 and
C2-16. As shown in Fig. 5.4a, the R306S mutation dramatically enhanced use of
lymphocyte CCR5 for 89.6. In addition, the R306S change also decreased CXCR4
mediated infection for the 89.6 mutant. Importantly, this dramatic shift in lymphocyte
coreceptor use occurred eventhough the mutant virus, like parental 89.6, remained R5X4
in indicator cells (Fig. 5.2b), albeit with some increase in relative CCR5 use associated
with the mutation. In fact, 89.6 R306S showed a preference for CCR5 use on
lymphocytes, in contrast to wild type 89.6, which was essentially restricted to CXCR4 for
entry into these cells (Fig. 5.4b). Unlike 89.6, CCR5 use on CD4+ lymphocytes by strain
C2-16 was not affected by the converse S306R mutation (Fig. 5.4a & b).
Thus, replacing the positively charged arginine with serine at residue 306 in the
89.6 Env increased the efficiency of CCR5 use, and resulted in preferential infection of
CD4+ lymphocytes through CCR5, reversing its otherwise strict dependence on CXCR4
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Figure 5.4. Residue 306 in Env regulates CCR5 use on CD4+ lymphocytes for 89.6 but not C2-16.
PHA stimulated CD4+ lymphocytes were infected with wild-type and mutant 89.6 and C2-16 luciferase
pseudotype viruses in the presence or absence of AMD3100, Maraviroc or a combination of both inhibitors.
The results are representative of the average of three experiments on cells from different donors each
performed in duplicate. The results are presented as the RLUs measured from cell lysates 4 days after
infection (A) or the RLUs for each treatment condition normalized to infection of untreated cells (B).
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in those cells. However, the amino acid at this position is not a critical determinant for
all R5X4 viruses, since converting serine to arginine at that residue did not notably
impact the efficiency of CCR5 use or coreceptor preference on primary lymphocytes by
the C2-16 Env, indicating that other context-dependent factors are involved as well.

Residue R306 increases Env dependence on the CCR5 amino terminus
Residue R306 is located in the stem of the V3 loop. This region of the V3 loop is
thought to interact with the CCR5 ECLs, and mutations or deletions at this site in other
Envs has been associated with changes in interaction with this coreceptor (Cormier and
Dragic, 2002; Gray et al., 2009; Nolan et al., 2009). To determine how mutations at
position 306 in Env impact interactions with CCR5, wt and mutant 89.6 and C2-16, along
with the R5 virus JRFL, were used to infect 293 cells that expressed CD4 and wt CCR5
or versions of this coreceptor containing deletions of the N-terminus. All coreceptors
were expressed at similar levels on the cell surface based on staining using the ECL2
mAb 2D7 (data not shown).
As shown in figure 5.5, infection by wt 89.6 was substantially reduced on cells
expressing CCR5 that lacked four N-terminal residues (∆2-5), and deletion of eight
amino acids from this domain (∆2-9) completely abolished infection by this virus.
Conversely, infection of cells expressing ∆2-5 by 89.6 R306S was two fold greater than
infection by wt virus, and unlike wt 89.6, the mutant virus used ∆2-9 to infect 293 cells
(Fig. 5.5a). For C2-16, the ∆2-5 deletion had minimal effect on infection by wt or mutant
virus, and neither virus efficiently used ∆2-13 for infection. However, infection of cells
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Figure 5.5. Envs with R306 are more dependent on the N-terminus of CCR5 for infection.
293 cells expressing CD4 and mutant CCR5 with either N-terminal deletions (A) or N-terminal Y to A
substitutions (B). Following transfection, cells were infected with 5ng of wt and mutant 89.6 and C2-16
luciferase pseudotypes. Results are shown as the luciferase activity in cell lysates from cells expressing
mutant coreceptor normalized to infection of 293 cell expressing wt CCR5 after 3 days in culture. Results
are representative of two infections each performed in triplicate.
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expressing ∆2-9 by wt and mutant C2-16 revealed stark differences in how these viruses
are affected by changes in the CCR5 N-terminus. While infection of cells expressing ∆29 by wt C2-16 was only 10% lower than infection using wt CCR5, the S306R conversion
resulted in a virus incapable of using this mutant coreceptor (Fig. 5.5a). Unlike the R5X4
viruses, JRFL was able to use all three truncated coreceptors for infection (Fig. 5.5a).
Thus, the identity of the residue at position 306 in Env is associated with different
requirements for the CCR5 N-terminus. Viruses with arginine at this position are more
dependent on the N-terminus of CCR5 for infection, and serine at this position is
associated with the ability to use CCR5 despite truncation of this domain.
There are four tyrosines in the N-terminus of CCR5, and these tyrosines can be
sulfated (Farzan et al., 1999). Tyrosine sulfation at residues 10, 14 and 15 in the CCR5
N-terminus are thought to be critical for gp120 binding and HIV-1 infection (Cormier et
al., 2000; Farzan et al., 1998; Farzan et al., 1999; Rabut et al., 1998). Since the residue at
position 306 regulates dependence on the N-terminus of CCR5, I thought it might also
regulate dependence on the tyrosines in this domain. Therefore, I sought to determine
whether altering the tyrosines in the CCR5 N-terminus had a larger impact on infection
by wt or mutant Env clones of 89.6 and C2-16, and if an arginine or a serine at position
306 was associated with increased sensitivity to tyrosine mutation. This was done by
infecting 293 cells that expressed CD4 and wt CCR5 or CCR5 mutants in which an
individual tyrosine is mutated to alanine. All coreceptors were expressed at similar levels
on the cell surface based on staining using the ECL2 mAb 2D7 (data not shown).
As shown in Fig 5.5b, infection by 89.6 on cells expressing the Y3A coreceptor
was less than half that mediated by wild-type CCR5, and infection of cells expressing the
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three other mutant coreceptors only approached 10% of wt levels (Fig. 5.5b). In contrast,
the 89.6 mutant carrying the R306S change was less affected by tyrosine mutation,
consistently reaching infection levels on each mutant at least 20% higher than infection
by wt virus, and use of the Y10A coreceptor was five fold greater for 89.6 R306S
compared to 89.6 (Fig. 5.5b). In contrast to 89.6, C2-16 was only modestly affected by
the individual tyrosine mutations, whereas changing serine to arginine (C2-16 S306R)
resulted in a virus with markedly reduced use of the Y14A and Y15A coreceptors, and
that was also less able to use the Y10A coreceptor. Interestingly, CCR5-mediated
infection by JRFL was only slightly affected by any of these individual tyrosine
mutations, which was similar to C2-16 and markedly different from 89.6 (Fig. 5.5).
Thus, the presence of arginine at position 306 is associated with increased dependence on
tyrosine residues in the N-terminus of CCR5, while serine at this position results in less
dependence on these residues.
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Conclusions
CCR5 use on CD4+ lymphocytes varies among the R5X4 strains, but it is
generally low, and includes one virus, 89.6, that is almost completely unable to use
lymphocyte CCR5 even after CCR5 expression is increased on these cells. The V3
domain in Env is a principal determinant of coreceptor use and interacts directly with the
coreceptor. In this chapter, I sought to determine the contribution of V3 to the spectrum
of CCR5 use by R5X4 strains.
Using a PSSM algorithm, I found that viruses with greater lymphocyte CCR5 use
were predicted to have an NSI phenotype while viruses that used this coreceptor poorly
were classified as SI viruses. Comparative analysis of V3 revealed that viruses at the
extremes of the lymphocyte CCR5 use spectrum, C2-16 and 89.6, could clearly be
distinguished by the absence or presence, respectively, of common hallmarks of CXCR4
use, including the charge of the residue at position 306 in Env. I mutated the amino acid
at this position in 89.6 (R306S) and C2-16 (S306R) to determine its role in controlling
CCR5 use by these viruses. My findings show that the R306S change in 89.6
dramatically enhanced lymphocyte CCR5 use and changed coreceptor preference on
these cells from CXCR4 to CCR5. However, the reciprocal mutation had no affect on
lymphocyte coreceptor use by C2-16. The presence of an arginine at position 306 was
associated with increased sensitivity to CCR5-specific blockers and less efficient
infection of Affinofile cells when compared to viruses with serine at this same position.
Having an arginine instead of a serine at residue 306 was also associated with greater
dependence on the CCR5 N-terminus for infection. These results indicate that elements
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within V3 determine the spectrum of lymphocyte CCR5 use by R5X4 strains, the amino
acid at position 306 in Env regulates the efficiency of CCR5 use for 89.6 and C2-16, and
R306 is responsible for the impaired use of lymphocyte CCR5 by 89.6.
The bridging sheet and base of V3 are thought to interact with the N-terminus of
CCR5, while the tip and stem interact with the ECLs (Cormier and Dragic, 2002;
Cormier et al., 2001; Huang et al., 2007). The data presented here imply that the greater
dependence on the CCR5 N-terminus displayed by R306 compared to S306 Envs results
from reduced interactions between V3 containing R306 and the CCR5 ECLs. Amino
acids 306 and 319/320 in V3 are thought to create a surface in Env that is positively
charged for X4 viruses or negatively charged for R5 strains (Cardozo et al., 2007). While
the charges of the residues at these positions for R5X4 strains do not always conform to
this rule, 89.6 has positive charges at both positions, and C2-16 has a neutral residue at
position 306 and a negatively charged residue at positions 320. Differences in the charge
of the surface created by amino acids 306 and 319/320 between 89.6 and C2-16 regulate
interactions with residues in the ECLs of CCR5, and the strength of this interaction
contributes to regulation of CCR5 use.
Residue 306 in Env regulated CCR5 use by both 89.6 and C2-16, with serine at
this position associated with more efficient Env-CCR5 interactions. Most of the R5X4
strains, including those with poor lymphocyte CCR5 use, had a neutral or acidic amino
acid at this position, suggesting other residues may be responsible for the pattern of
CCR5 use by these strains. Positions 306 and 319/320 likely associate in space, and
perhaps the amino acid at either of the later positions could contribute to regulation of
lymphocyte CCR5 use by some of these strains. The majority of the variability between
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the V3 sequences of these R5X4 Envs is on either side of the tip, in residues that contact
the ECLs. For some viruses, basic amino acids are found at these residues, and perhaps
these amino acids negatively contribute to Env-CCR5 interactions. However, some of
the R5X4 viruses with poor lymphocyte CCR5 use had no positive charges at either of
these positions, and for these Envs, other domains may play an important role. For
instance, the V1-V2 region of DH12 can confer CXCR4 use to an R5 virus, and Nglycosylation in this domain in the DH12 Env also influences the efficiency of CCR5 or
CXCR4 use (Cho et al., 1998; Ogert et al., 2001). Thus, while I show that regulation of
lymphocyte CCR5 use by the R5X4 strain 89.6 is influenced by interactions between the
ECLs and the residue at position 306, additional factors exist likely, both within and
outside V3, that regulate this interaction.
The R306S change in the 89.6 Env was also associated with a decrease in the
contribution of CXCR4 to infection of CD4+ lymphocytes. V3 loops of X4 viruses have
higher net positive charges than R5 viruses, and it has been proposed that this higher
charge allows X4 viruses to utilize the negatively charged surface of CXCR4 (Chabot et
al., 1999). Deletion of residues 304-307 in the R3A and 89.6 Env abrogates CXCR4 use
by these viruses, suggesting this region is critical for interactions with the CXCR4 ECLs
(Nolan et al., 2009). Thus, it is plausible that the amino acid at position 306 also
contributes to regulation of CXCR4 use for some R5X4 viruses and that S306 is
associated with reduced interactions with the CXCR4 ECLs.
It is interesting that changing the amino acid at position 306 had an impact on
every measure of how efficiently 89.6 and C2-16 mutants used CCR5, but the S306R
mutation did not alter CCR5 use on primary lymphocytes by C2-16. The V3 loop of C292

16 has features that are very similar to R5 viruses, including a low net positive charge
(+3) and the lack of positively charged amino acids at the two key residues in the V3
stem. The S306R mutation introduces a positive charge into Env, which should decrease
interactions with the CCR5 ECLs. It is possible that other residues within C2-16 Env
continue to contact critical determinants in the ECLs, and, as a result, CCR5 use by the
C2-16 mutant might be less affected. An alternative possibility is that the density of
CCR5 expressed on lymphocytes is above the threshold required by both wt and mutant
C2-16, and this would make it is difficult to observe a difference in lymphocyte CCR5
use by the two strains. Presently, it is unclear what accounts for the robust use of
lymphocyte CCR5 by the C2-16 mutant.
PSSM predictive algorithms are not highly accurate for distinguishing R5X4 from
single coreceptor-tropic viruses, but we found that among R5X4 variants, the SI/NSI
matrix showed a strong correlation between “NSI-like” characteristics and greater
lymphocyte CCR5 use, and “SI-like” and poorer lymphocyte CCR5 use. These results
further support the role of V3 in determining coreceptor preference in the context of
primary cells and, in addition, further emphasize the limitations of indicator cells in
predicting primary cell coreceptor use. In contrast, the X4/R5 predictive matrix, based on
coreceptor use in indicator cell lines, did not distinguish between R5X4 strains with
greater or lesser lymphocyte CCR5 use. Future studies will be needed to characterize the
strains for which phenotype predictions differ between the scoring matrices, and
determine whether these Envs may exhibit other distinguishing features in their
interactions with primary cells.
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The role of particular Env domains in determining CCR5 or CXCR4 use has been
well studied, however, the exact mechanisms underlying the discrimination of CCR5 and
CXCR4 are still obscure. Small changes in the viral Env can impact interactions with
different domains of the coreceptor, and this can affect viral entry. However, it is
currently not known whether the structural determinants of CCR5 are equally exposed on
different primary cell types or cells from different donors. These questions have
important implications for the design of coreceptor antagonists and the study of drug
resistance. Thus, understanding how changes in the HIV-1 Env alters interactions with
the CCR5 structure and impacts primary cell coreceptor use is an extremely important
topic.
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Chapter VI - Discussion
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R5X4 strains are usually the first CXCR4-using viruses to emerge, and these
variants appear late in disease with varying frequency in people infected with HIV-1
from many of the group M subtypes (van Rij et al., 2000; Zhang et al., 1997; Zhang et al.,
1998). During the acute and early phases of disease, R5 strains predominate (Liu et al.,
1996; Samson et al., 1996). However, R5X4 strains also use CCR5 but fail to establish
infections in recipients. Selection against CXCR4 using variants may be the reason
R5X4 viruses rarely seed new HIV-1 infections. Alternatively, R5X4 strains may fail to
transmit because CCR5 use by these variants is distinct from coreceptor use by R5
strains. The study of coreceptor use by R5X4 viruses may provide key insights into this
important aspect of HIV-1 infection.
Coreceptor use by HIV-1 strains is typically determined on cell lines that have
been engineered to express CD4 and a coreceptor, and infection of these cell lines
indicates which coreceptors a virus can use. However, viruses may fail to infect primary
cells using a coreceptor that it uses in indicator cell lines, raising questions of whether
coreceptor use on cell lines accurately models coreceptor use on primary cells (Tokunaga
et al., 2001). The primary cell targets of HIV-1 express CCR5 and CXCR4, and a
previous study from our lab demonstrated that prototype R5X4 viruses use CCR5 and
CXCR4 to infect macrophages. However, infection of CD4+ lymphocytes occurred
predominately through CXCR4, whereas CCR5 was used poorly, if at all (Yi, Shaheen,
and Collman, 2005). For this dissertation, I utilized a variety of dual-tropic isolates
representing a broad spectrum of phenotypes, to assess whether R5X4 strains vary in the
ability to use CCR5 on lymphocytes, and what factors determined the use of this
pathway.
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Limited lymphocyte CCR5 use: implications for the evolution and transmission of
R5X4 HIV-1
Results presented in this dissertation indicate limited CCR5-mediated infection of
CD4+ T cells by the R5X4 strains tested, which did not substantially contribute to overall
infection levels when CXCR4 was available. However, blocking CXCR4 use revealed a
spectrum of lymphocyte CCR5 use among the R5X4 viruses. CCR5 is expressed on a
small percentage of CD4+ T cells, and increasing CCR5 expression noticeably improved
CCR5 use for all R5X4 strains, except 89.6. If CCR5 use was determined strictly by the
percentage of cells expressing this coreceptor, then infection by R5X4 strains should be
equivalent to that of R5 viruses. CCR5 density varies within the population of CD4+
lymphocytes, and the variability in lymphocyte CCR5 use by R5X4 strains suggested that
coreceptor density could be a factor in regulating lymphocyte CCR5 use. However, other
additional factors likely exist, since CCR5-mediated infection of CD4+ lymphocyte by
89.6 was not enhanced by increasing CCR5 expression. R5X4 and R5 strains with the
greatest CCR5 use were proficient at detecting this coreceptor than antibody specific for
CCR5, suggesting Env might also regulate use of this coreceptor on CD4+ lymphocytes.
The R5X4 strains in this report exhibited a spectrum in their efficiency of
lymphocyte CCR5 use, but none preferentially infected CD4+ T cells using this
coreceptor. On one hand, this is not surprising given the difference in number of cells
positive for each coreceptor. On the other hand, R5X4 strains emerge in vivo from R5
strains in memory lymphocytes that express CCR5 and CXCR4, while later in infection,
R5X4 along with X4 viruses are found mostly in the CCR5-/CXCR4+ naïve subset (van
Rij et al., 2000). Thus, it seems likely that some R5X4 strains would use CCR5 as the
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predominant coreceptor to infect CD4+ T cells. The fact that the R306S mutation in 89.6
changes coreceptor preference on lymphocytes from CXCR4 to CCR5 indicates that this
type of R5X4 Env can exist and that only minor changes may be required to shift
between these two phenotypes. Perhaps R5X4 viruses that predominately use CCR5 to
infect lymphocytes emerge but then rapidly disappear from the viral quasispecies.
Alternatively, evolution of R5X4 strains might never transit through a phase in which
CCR5 use is dominant. In a study of in vitro-derived R5X4 switch variants, the earliest
CXCR4-using Envs were more sensitive to CCR5 antagonists and less efficient at using
CCR5 for entry when compared to the parental R5 virus (Pastore, Ramos, and Mosier,
2004), and the mutations conferring CXCR4 use were detrimental except when
introduced with compensatory changes elsewhere in the envelope (Pastore et al., 2006).
In vivo, R5 strains showed reduced ability to infect CCR5-low cells prior to the
emergence of R5X4 viruses (Coetzer et al., 2008). Thus, CXCR4 use may only emerge
after compensatory mutations occur that have the effect of decreasing CCR5 use,
suggesting that R5X4 evolution may not involve a phase of predominate lymphocyte
CCR5 use.
R5 viruses are responsible for establishing the majority of new HIV-1 infections,
but it is still not clear why. R5 strains are typically more macrophage-tropic than X4
variants, and CCR5-dependent macrophage tropism was classically proposed as a
possible reason (Liu et al., 1996; van't Wout et al., 1994; Zhu et al., 1993). However,
R5X4 strains also use CCR5 to infect primary macrophages, yet this strain is rarely
transmitted (Liu et al., 1996; van't Wout et al., 1994; Yi, Shaheen, and Collman, 2005).
Furthermore, recent studies using transmission pair isolates obtained near the time of
98

transmission enabling donor/recipient comparison, or PCR amplification and
phylogenetic reconstruction of the successfully transmitted virus, reveal that these
founder viruses are restricted to CCR5 and readily infect lymphocytes but typically infect
macrophages inefficiently and/or no better than the donor variants (Isaacman-Beck et al.,
2009; Keele et al., 2008b; Salazar-Gonzalez et al., 2009). The fact that R5X4 variants
generally use lymphocyte CCR5 poorly relative to R5 viruses raises the possibility that
these strains do not establish infections in recipients because use of CCR5 on
lymphocytes is the critical determinant of transmission. Alternatively, it remains possible
that neither R5X4 nor X4 strains efficiently transmit because CXCR4 use is selected
against during transmission or establishment of new infections in recipients (Cornelissen
et al., 1995).

Efficiency of CCR5 use by R5X4 HIV-1: implications for pathogenesis
The variability in lymphocyte CCR5 use among the R5X4 strains, coupled with
the observations that Envs at the extremes of this spectrum appeared to use CCR5 with
different efficiencies, suggested that Env-coreceptor interactions influenced lymphocyte
CCR5 use by R5X4 strains. Experiments with CCR5-specific mAbs showed a significant
correlation between greater lymphocyte CCR5 use and reduced sensitivity to ECL-2, but
not N-terminal or multi-domain mAbs. When sensitivity to entry inhibitors was assessed,
reduced sensitivity to CCR5 small molecule antagonists, but not fusion inhibitor T20,
also correlated with greater lymphocyte CCR5 use. The link between coreceptor use and
the efficiency of the Env-CCR5 interaction was further evaluated using cell lines with
99

regulated levels of CD4 and CCR5. At physiologically relevant CD4 levels, R5X4
strains with greater lymphocyte CCR5 use were less sensitive to reductions in CCR5
density. Moreover, there was a significant correlation between the ability to exploit low
levels of CCR5 on this cell line and higher levels of lymphocyte CCR5 use. These
results suggest that variation in the efficiency of Env interactions with the ECLs of CCR5
has an effect on efficiency of coreceptor use and contributes to the spectrum of
lymphocyte CCR5 use by R5X4 strains. These findings underscore the importance of the
ECLs, in particular ECL2, in infection by R5X4 viruses, and raise the possibility that
determinants in Env ultimately regulate lymphocyte CCR5 use by these viruses.
The limited CCR5-mediated infection of lymphocytes by R5X4 HIV-1 raises
questions of whether the efficiency of CCR5 use by R5X4 viruses has any impact on
viral pathogenesis. Although rare, R5X4 strains have been transmitted and were able to
establish infection in recipients (Meissner et al., 2004; Yu et al., 1998). Given the
importance of CCR5 use in transmission, these viruses might be expected to utilize
lymphocyte CCR5 more efficiently than R5X4 viruses that arise later. Strain R3A was
obtained from an unusual R5X4 acute infection (Meissner et al., 2004), but R3A was not
among the R5X4 Envs with more efficient lymphocyte CCR5 use. Paradoxically, the
two variants with greatest relative efficiency in lymphocyte CCR5 use were NR10, from
a late stage patient, and C2-16, from a CCR5-null subject; neither are clinical scenarios in
which one might expect more efficient lymphocyte CCR5 use from the isolated virus.
Macrophage infection is thought to be the major source of virus in tissue, a critical
component of neuropathogenesis, and responsible for sustaining virus replication at very
late stages of disease (Igarashi et al., 2001; Koenig et al., 1986; Schuitemaker et al.,
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1992). Prototype and some primary R5X4 strains readily infect macrophages using
CCR5, which may be explained by the higher density of CCR5 expressed on these cells
compared with primary CD4+ lymphocytes (Lee et al., 1999b; Yi, Shaheen, and
Collman, 2005). However, use of this coreceptor may be dispensable since CXCR4 also
serves as a viable coreceptor for R5X4 entry into these cells (Yi, Shaheen, and Collman,
2005). Thus, it remains to be determined how the efficiency of lymphocyte CCR5 use
among R5X4 variants is linked to specific aspects of pathogenesis. In addition, while X4
use is common in subtype B HIV-1, it is less frequent among subtype C strains and,
furthermore, the factors that regulate coreceptor interactions may differ for different
subtypes (Lynch et al., 2009). Further studies will be needed to determine the extent to
which these findings apply to other subtypes

V3 determinants that regulate CCR5 use by R5X4 HIV-1: implications for structural
interactions with coreceptor
The repeated correlation between measures of Env-CCR5 interaction efficiency
and CCR5 use on lymphocytes suggested that elements within Env regulate lymphocyte
CCR5 use. Since V3 is the principal determinant of coreceptor use, I focused on how
variation in this domain might regulate lymphocyte CCR5 use by R5X4 strains. I
discovered a relationship between the viral phenotype predicted using a V3-based PSSM
algorithm and lymphocyte CCR5 use, with viruses that used this coreceptor well
predicted to be NSI viruses and those that use it poorly identified as SI variants.
Subsequent analysis of V3 sequences revealed that the two variants at the extremes of the
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spectrum of CCR5 use, 89.6 and C2-16, differed in the presence of hallmarks associated
with CXCR4 use, including the presence or absence, respectively, of a basic amino acid
at position 306 in V3. Evaluation of mutant compared to wt viruses showed that 89.6
R306S was less sensitive to blocking CCR5 and was less dependent on the CCR5 Nterminus for infection. Conversely, the C2-16 S306R mutant was more sensitive to
agents directed at CCR5 and was more dependent on the N-terminus of the coreceptor.
The impact of these mutations on coreceptor use was determined by infecting primary
lymphocytes, and the results indicated that the R306S mutation in 89.6 changed its
coreceptor preference from CXCR4 to CCR5, while the reciprocal S306R change in C216 did not alter coreceptor use. These studies revealed that features within V3 likely
determine the spectrum of lymphocyte CCR5 use, that the residue at position 306 in Env
modulates the efficiency of CCR5 use for 89.6 and C2-16, and that R306 is responsible
for impaired lymphocyte CCR5 use by 89.6.
The V3 domain is a primary determinant of coreceptor use, however, the effect of
subdomains within this region on primary cell coreceptor use has not been previously
addressed. Here, I show that a serine at position 306 is associated with greater
lymphocyte CCR5 use by 89.6. This occurs because serine at this residue enhances the
efficiency of CCR5 use, likely through enhanced interactions with the CCR5 ECLs.
Most of the R5X4 strains have serine at this position, but not all use CCR5 efficiently.
PSSM results indicate that elements within V3 likely regulate lymphocyte CCR5 use by
R5X4 viruses. The majority of the variation in the V3 region is in stem and tip residues
other than 306. Thus, these stem and tip residues may regulate lymphocyte CCR5 use for
the other R5X4 strains. This would presumably occur through interactions with the
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ECLs, since the V3 stem and tip are thought to interact with this domain of the
coreceptor. Interestingly, the C2-16 S306R mutation had an impact on the efficiency of
CCR5 use by C2-16, but did not alter its coreceptor use on primary lymphocytes. The
reasons for this are unclear, but may involve other regions of Env or of V3. Additionally,
mutations at this position also affected CXCR4 use by 89.6, suggesting that residue 306
may regulate interactions with CXCR4 for some viruses.
The ability to use CCR5 and CXCR4 must hinge on the ability of R5X4 strains to
recognize conserved regions of each coreceptor, but it is unclear exactly how this is
regulated. Numerous studies indicate that the underlying architecture of CCR5 and
CXCR4 are similar. R5, X4 and R5X4 viruses are capable of using CCR5/CXCR4
chimeras for infection, even when multiple discontinuous domains are exchanged
(Karlsson et al., 2004; Pontow and Ratner, 2001). Removal of an N-linked glycosylation
site in the N-terminus or a substitution that removes a negatively charged residue in ECL2 of CXCR4 permits use of this coreceptor by R5 viruses (Chabot and Broder, 2000;
Chabot et al., 2000; Chabot et al., 1999). As mentioned, deletion of amino acids
surrounding the V3 loop of R3A and 89.6 abrogated CXCR4 use; the resulting virus
retained CCR5 use but was resistant to CCR5 antagonists (Nolan, Jordan, and Hoxie,
2008). These findings indicate this segment of the V3 stem interacts with the ECLs of
CCR5 and CXCR4. Residue 306 is located in this region of V3 and it modulates EnvCCR5 and potentially Env-CXCR4 interactions for some viruses. Perhaps position 306
serves as a pivot point in Env, and the identity of the amino acid at this position allows
the virus to favor one coreceptor over another by recognizing a critical ECL determinant
that is similar in both coreceptors but distinct enough to allow the virus to distinguish
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CCR5 from CXCR4. For other R5X4 strains, in which amino acid 306 may not regulate
the efficiency of CCR5 use, another stem or tip residue in V3 may play this role.
Summary and final conclusions
In summary, using a panel of primary and prototype R5X4 HIV-1 variants, this
study confirms that these strains are highly skewed towards CXCR4 use for entry into
CD4+ T cells. However, among the isolates tested, there is a range in the relative ability
to use CCR5 on primary lymphocytes, although we did not identify an evident
relationship between relative lymphocyte coreceptor use and the clinical context in which
the R5X4 Envs were derived. The ability to use lymphocyte CCR5 by R5X4 variants
was linked to greater efficiency in CCR5 interactions based on antibody and small
molecule antagonist blocking studies, and this was dependent on residues within V3.
Furthermore, the barrier to CCR5 use could be overcome by CCR5 over-expression in
lymphocytes for most of the R5X4 isolates or, by mutating Env to enhance coreceptor
interaction efficiency.
These finding lead to the conclusion that potential CCR5-mediated infection of
CD4+ lymphocytes is limited by the proportion of cells that express CCR5, but actual
CCR5 use by a specific R5X4 virus is regulated by the threshold of CCR5 it requires for
infection. The differences in CCR5-Env interactions identified among the R5X4 strains
here, which are dependent on determinants within the Env V3 that interact with the
CCR5 ECLs, regulate the threshold of CCR5 required for entry. Thus, the efficiency of
the Env-CCR5 interaction is the principal factor underlying differences in CCR5mediated target cell availability and, ultimately, lymphocyte CCR5 use for each isolate.
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Better understanding of the viral and cellular factors that control coreceptor use by HIV-1
strains is critical to understanding the impact of viral evolution on target cell tropism.
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